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prostate cancer 
Mr iMaging 
Derya yakar
(recurrence) anD guiDing interventions
in the localization of
stellingen bij het proefschrift
Mr iMaging in localizing prostate cancer (recurrence) 
and guiding interventions
1. op basis van de literatuur, lijkt MP-Mri de beste beschikbare beeldvormende 
techniek op dit moment in het lokaliseren, het stadiëren, het bepalen van 
agressiviteit, en het volume van prostaatkanker (dit proefschrift).
 2. op basis van de literatuur, is het aanbevolen om voor de lokalisatie van 
prostaatkanker een MP-Mri te verrichten bestaande uit ten minste t2-w, Dce-
Mri, en DWi (dit proefschrift).
 3. het gebruik van een erc in 3D Mrsi in het lokaliseren van prostaatkanker op 
3t geeft slechts in geringe mate een verbetering in vergelijking met het niet 
gebruiken van een erc (dit proefschrift).
 4. Dce-Mri gerichte MrgB bij patiënten met een biochemisch recidief na 
radiotherapie van prostaatkanker is een haalbare techniek (dit proefschrift).
 5. volgens de literatuur zijn detectiepercentages van MrgB van de prostaat bij 
patiënten met een voorgeschiedenis van eerdere negatieve trusgB sessies 
hoger dan herhaalde trusgB sessies (dit proefschrift).
 6. het is mogelijk om transrectale prostaatbiopsie uit te voeren met 3t Mri 
begeleiding en met behulp van een op afstand bestuurbare Mr-compatibele 
robot als hulpmiddel (dit proefschrift).
 7. transperineale Mr-geleide focale cryo-ablatie van prostaatkankerrecidief na 
radiotherapie is uitvoerbaar en veilig (dit proefschrift).
8. i was working on the proof of one of my poems all the morning, and took out a 
comma. in the afternoon i put it back again (oscar Wilde).
9. it’s possible that i understand better what’s going on, or it’s equally possible that i 
just think i do (russ cox). 
10. the time you enjoy wasting is not wasted time (Bertrand russell). 
Derya yakar
lent, augustus 2012
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introduction
Prostate cancer (PCa) is a significant health burden. In developed countries it 
is the most commonly diagnosed form of male cancer. in terms of estimated 
cancer deaths it is the third leading cause after lung and colorectal cancer 
(1). as in all cancers, when diagnosed in an early stage a successful curative 
management plan is attainable.
 in the diagnosis of Pca parameters such as tnM stage, aggressiveness 
(represented by the gleason score), and volume estimation are essential to both 
treatment choice as well as its success. urologists base their every day decision-
making on nomograms that have incorporated these parameters (2).
 however, the generally used diagnostic methods, like digital rectal 
examination (DRE), prostate specific antigen (PSA)-level, and gray scale 
transrectal ultrasound (trus)-guided biopsy, which are the input for these 
nomograms, are imperfect. DRE misses a substantial proportion of significant 
cancers and identifies predominantly tumours when they are large and in a 
more advanced pathologic stage (3, 4). Psa is considered as the most useful 
tumour marker for diagnosis, staging and monitoring of Pca. it correlates well 
with advanced clinical and pathological stages in most cases, but due to low 
specificity it cannot accurately stage an individual patient, as there is large 
overlap between different tumour stages (5). also, other benign causes such 
as benign prostatic hyperplasia and prostatitis can cause elevated Psa levels. 
shortcomings of gray scale trus-guided prostate biopsy are an inherently low 
sensitivity for detection of Pca (6), a high false-negative biopsy rate and over- or 
underestimating of the true gleason score (2, 7). More rigorous biopsy schemes 
such as three dimensional (3D) template-guided transperineal saturation biopsies 
-up to 80 cores- have shown to augment cancer detection rates to some degree 
(8-10). nevertheless, such drastic biopsy methods have many drawbacks like 
patient discomfort, complication rates, the need of anaesthetics, and intensive 
pathologic processing. other biopsy methods such as magnetic resonance 
guided biopsy (MrgB) has also been the subject of various research articles. The 
purpose of chapter 5 and 6 is to give an overview on the literature concerning 
MRGB.
 in summary, Psa, Dre, and trus guided biopsy do not have the ability to 
correctly localize, stage, determine volume, and aggressiveness of Pca. in the 
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new era of more precise therapy forms such as intensity modulated radiation 
therapy (iMrt) and focal ablative therapies (e.g. cryosurgery, high-intensity-
focused ultrasound, laser therapy, and radiofrequency ablation), this information 
is of utmost importance. 
 the ideal Pca assessment tool should be able to gather this information in a 
non-invasive way. this information can then serve therapy choice, and guidance 
of interventions and treatments. 
 Magnetic resonance (Mr) imaging in the assessment of Pca has been used 
for multiple indications, e.g. detection of Pca in patients with elevated/rising 
Psa level and multiple prior negative trus-guided biopsy sessions, localization, 
detection of recurrent disease, staging local as well as distant disease, and 
guiding biopsies (11). The purpose of chapter 2 is to give an extensive overview 
on the potential role of multi-parametric (MP) MR imaging in focal therapy with 
respect to patient selection and directing (robot guided) biopsies and IMRT. a 
part of this introduction is based on the aforementioned review in chapter 2. 
localization of pca
localizing Pca is important in clinical situations in patients with a rising Psa and previous 
negative biopsies. imaging can serve in such situations for guiding biopsies. also, 
localizing Pca is important in determining the cancer’s distance to the neurovascular 
bundle, the prostate capsule, and other adjacent organs. This information influences 
therapy choice. in localizing Pca with Mr imaging, studies report on the incremental 
value of MP-Mr imaging, such as dynamic contrast-enhanced (Dce-Mri), diffusion 
weighted imaging (DWi), and Mr spectroscopic imaging (Mrsi) (12-17), as opposed 
to anatomical t2-weighted (t2-w) imaging only. areas under the curve of 0.90 when 
t2-w, Dce-Mri and Mrsi were combined in localizing Pca have been reported (14). 
it is therefore recommended to perform MP-Mr imaging consisting of at least t2-w, 
and 2 functional Mr imaging techniques such as Dce-Mri, and DWi/ Mrsi. however, 
the lack of consensus in imaging protocols (e.g. with/without endorectal coil, field 
strengths, b-values, post-processing methods) makes defining definite guidelines 
troublesome. A first step was taken by the European Society of Urogenital Radiology 
group, which resulted in a guideline with minimal and optimal imaging acquisition 
protocols (18). The purpose of chapter 3 is to compare the diagnostic performance 
of 3 Tesla (3T), 3-dimensional 3D MRSI in the localization of PCa with and without the 
use of an endorectal coil (ERC).
17
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recurrent pca after radiotherapy and Mr-guided prostate biopsy
the majority of patients with Pca is either treated with radical prostatectomy 
or radiotherapy. approximately 30% will experience biochemical recurrent 
disease (19). currently, Psa elevation after rt is the best indicator of biologically 
active tumour (20, 21). Whenever such an elevation of Psa has taken place, 
the main objective is to find out whether the increase in PSA is due to local or 
distant recurrent disease. imaging is required, as further detailed information 
about the site of recurrence is needed. Detecting local recurrent disease in the 
prostate after radiotherapy is difficult with conventional imaging techniques. The 
prostate will be characterized by a diffuse low signal on t2-w Mr images (22, 
23). for this reason, t2-w Mr imaging is less helpful in localizing recurrence of 
Pca. gadolinium-based contrast agents are of added value. studies evaluating 
DCE-MRI after radiotherapy report sensitivities between 70%-74% and specificities 
between 73%-85% (24, 25). the incremental value of DWi and Mrsi in localizing 
Pca after rt has also shown to be useful (26, 27).
 recurrent cancer suspicious regions (csrs) seen on MP-Mri can be targeted 
for biopsy. this can be done by either performing a trus-guided biopsy, a trus-Mr 
fusion guided biopsy, or an MrgB. no studies have been performed comparing 
these different biopsy methods. MrgB has shown to improve the cancer detection 
rate in subjects with an elevated Psa and repetitive negative trus-guided biopsies 
(28-30). no studies have investigated MrgB in patients with a biochemical 
recurrence after radiotherapy. The purpose of chapter 4 is to assess the feasibility 
of the combination of diagnostic 3T MR imaging and MRGB in the localization of 
local recurrence of PCa after external beam radiation therapy (EBRT).
Mr-compatible robot for transrectal prostate biopsy
so far, the only commercially available Mr-guided prostate biopsy device is a 
manually adjustable standard for needle guide positioning (30, 31). the radiologist 
has to adjust the needle guide into the direction of the region of interest by 
hand, based on Mr images (31). consequently, the patient has to be moved 
in and out of the scanner bore each time to adjust the direction of the needle 
guide. it is conceivable that during these time consuming manoeuvres, there is 
abundance of time for movement of the patient as well as movement of the 
prostate, possibly leading to less accuracy. furthermore, one can imagine that 
this procedure is unpleasant for the patient. for these reasons an Mr-compatible 
18
robot for transrectal prostate biopsy has been developed and investigated. 
The purpose of chapter 7 is to assess the feasibility of a remote controlled, 
pneumatically actuated, MR-compatible, robotic device as an aid to perform 
transrectal biopsy in the prostate with real-time 3T MR imaging guidance.
focal Mr-guided cryo-ablation of pca recurrence after radiotherapy
after radiotherapy recurrence, salvage prostatectomy is a treatment option. 
however, high rates of incontinence (0-67%) or rectal injury (0–8%) (32, 33) 
have led to the search for other salvage treatment options. for this reason, 
ablative techniques such as cryo-ablation, high intensity focused ultrasound, 
and photodynamic therapy have been developed. cryo-ablation, performed 
under trus guidance is an established treatment option for both men with newly 
diagnosed as well as recurrent Pca (34). nevertheless, in the new era of focal 
therapies Mr image guidance may be a more suited imaging method. MP-Mr 
imaging enables an accurate localization of the recurrent cancer as well as image 
guidance during the treatment itself. this way the recurrent cancer is treated and 
non-cancerous prostate tissue and nearby critical structures are kept away at a 
safe distance, potentially leading to less treatment related complications. The 
purpose of chapter 8 is to assess the feasibility of MR guided focal cryoablation 
at 1.5T in patients with locally recurrent PCa after initial radiotherapy.
aiM and outline of this thesis
the aim of chapter 2 is to provide an overview on the potential role of MP-Mr 
imaging in focal therapy with respect to patient selection and directing (robot 
guided) biopsies and iMrt. it discusses the role of MP-Mri in the localization, 
staging, volume estimation, assessment of aggressiveness, and guidance of 
radiotherapy and biopsies in Pca.
the aim of chapter 3 is to compare the diagnostic performance of 3t, 3D Mrsi in 
the localization of Pca with and without the use of an erc. this is investigated in 
18 patients, using histopathology as the standard of reference. omitting the use 
of an erc could save time, costs, and patient discomfort. 
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the aim of chapter 4 is to assess the feasibility of the combination of diagnostic 3t 
Mr imaging and MrgB in the localization of local recurrence of Pca after eBrt. this 
is evaluated in 24 patients. all patients underwent a diagnostic 3t Mr examination 
of the prostate consisting of t2-w and Dce-Mri. gadolinium-based Mr imaging 
techniques can be useful in not only localizing local recurrence after radiotherapy 
but probably also in guiding MrgB. 
the aim of chapter 5 and 6 is to provide a review concerning MrgB of the 
prostate. an overview of the literature, technical details, and future developments 
is discussed. 
the aim of chapter 7 is to assess the feasibility of a remote controlled, pneumatically 
actuated, Mr-compatible, robotic device as an aid to perform transrectal biopsy 
in the prostate with real-time 3t Mr imaging guidance. this is evaluated in 10 
patients. 
the aim of chapter 8 is to assess the feasibility of Mr guided focal cryo-ablation 
at 1.5t in patients with locally recurrent Pca after initial radiotherapy. this is 
investigated in 10 patients. all patients are followed up with MP-Mri to monitor 
treatment induced changes and Psa measuring. also treatment complications 
are recorded carefully.
in chapter 9 the general results are summarized and discussed. chapter 10 
provides a Dutch translation of these findings. 
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abstract 
Multi-parametric Mr imaging has the potential of being the ideal prostate cancer 
(Pca) assessment tool. information gathered with multi-parametric Mr imaging 
can serve therapy choice, guidance of interventions, and treatments. 
 the purpose of this review is to discuss the potential role of multi-parametric 
Mr imaging in focal therapy with respect to patient selection and directing 
(robot guided) biopsies and intensity modulated radiation therapy. 
 Multi-parametric Mr imaging is a versatile and promising technique. it 
appears to be the best available imaging technique at the moment in localizing, 
staging (primary as well as recurrent disease, and local as well as distant 
disease), determining aggressiveness, and volume of Pca. however, larger 
study populations in multi-centre settings have to confirm these promising results. 
however, before such studies can be performed, more research is needed in 
order to achieve standardized imaging protocols.
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introduction
in the diagnosis of Pca parameters such as location, tnM stage, aggressiveness 
(represented by the gleason score), and volume estimation are essential to both 
treatment choice as well as its success. urologists base their every day decision 
making on nomograms which have incorporated these parameters (1). 
 however, the generally used diagnostic methods, like digital rectal examination 
(DRE), prostate specific antigen (PSA) level, and gray scale transrectal ultrasound 
(trus)-guided biopsy, which are the input for the nomograms, are imperfect. 
DRE misses a substantial proportion of cancers and identifies predominantly 
tumours when they are large and in a more advanced pathologic stage (2;3). 
Psa is considered as the most useful tumour marker for diagnosis, staging and 
monitoring of Pca. it correlates well with advanced clinical and pathological 
stages in most cases, but due to low specificity it cannot accurately stage an 
individual patient, as there is large overlap between different tumour stages (4). 
shortcomings of gray scale trus-guided prostate biopsy are an inherently low 
sensitivity for detection of Pca (5), a high false-negative biopsy rate and over- or 
underestimating of true Gleason score (1;6). More rigorous biopsy schemes such 
as three dimensional (3D) template-guided transperineal saturation biopsies -up 
to 80 cores-, have shown to augment cancer detection rates (7-9). nevertheless, 
such drastic biopsy methods have many drawbacks for like patient discomfort, 
the need of anaesthetics, and intensive pathologic processing.
 in summary, Psa, Dre, and trus guided biopsy do not have the ability to 
correctly localize, stage, determine volume, and aggressiveness of Pca. in the 
new era of more precise therapy forms such as intensity modulated radiation 
therapy (iMrt) and focal ablative therapies (e.g. cryosurgery, high-intensity-
focused ultrasound, thermal therapy, and radiofrequency ablation), this 
information is of utmost importance. 
 the ideal Pca assessment tool should be able to gather this information in a 
non-invasive way. this information can then serve therapy choice, guidance of 
interventions, and treatments. Multi-parametric Mr imaging has the potential of 
being such a tool. 
 the purpose of this review is to discuss the potential role of multi-parametric 
Mr imaging in focal therapy with respect to patient selection and directing 
(robot guided) biopsies and iMrt.
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localizing pca
Screening, detection and localization
Mr imaging has been applied in the assessment of Pca for multiple purposes. it 
has been used for screening, detection in patients with elevated Psa level and 
multiple negative trus-guided biopsy sessions, recurrent disease, localization, 
and staging local as well as distant.
 the reported diagnostic performance of t2-weighted (t2-w) imaging in 
the detection and localization of Pca has a wide range with sensitivities and 
specificities between 47.8 – 88.2% and 44.3 – 81%, respectively (10-14). Therefore, 
the incremental value of multi-parametric Mr imaging such as dynamic contrast-
enhanced (Dce-Mri), diffusion weighted imaging (DWi), and Mr spectroscopic 
imaging (Mrsi) has been investigated. studies reporting on the combination 
of these techniques describe the additional value in diagnostic performance 
(11;12;14- 20). Fütterer et al. reported an area under the curve (AUC) of 0.90 when 
t2-w, Dce-Mri and Mrsi were combined in localizing Pca. it is recommended to 
perform multi-parametric Mr imaging consisting of at least t2-w, Dce-Mri, and 
DWi. however, the lack of consensus in imaging protocols (e.g. with/without 
endorectal coil, field strengths, b-values, post-processing methods) makes 
defining definite guidelines troublesome. Hence, the next focus point in future 
studies should be optimizing these protocols and reaching consensus.
staging 
Local 
t2-w, endorectal coil imaging, according to a meta-analysis by engelbrecht et al. 
reported a maximum combined sensitivity and specificity of 71% in distinguishing 
clinical stages t2 and t3 at a 1.5t Mr system (18). More recent studies, report maximum 
sensitivities and specificities of between 80%-88% and 96%-100%, respectively at a 3T 
MR system (22;23). Adding metabolic information obtained with MRSI to T2-w imaging 
improves staging accuracies (24). conjunction of this information with nomograms, 
used in daily clinical practice by urologists, in evaluating extracapsular extension 
and seminal vesicle invasion in staging Pca yields higher accuracies (25-27). in less 
experienced readers of Mr imaging in staging Pca also Dce-Mri appears to be of 
added value (28). Presumably, the extra information collected with Dce-Mri, DWi, 
and Mrsi draws the attention of the reader, more than t2-w imaging alone, to areas 
where extracapsular extension could be the case (figure 1).
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Skeletal 
assessment of skeletal metastases is mostly done by performing a technetium-
99m-diphosphonate bone scintigraphy. although bone scintigraphy is considered 
as the gold standard for skeletal imaging, its low positive yield makes its use 
controversial (29). several studies have evaluated the role of this technique 
compared to Mr imaging in detecting skeletal metastases (30-33), but only one 
study conducted this in a patient group with only prostate cancer as primary 
cancers (33). according to this study, Mr imaging when used alone, is superior 
in detecting bone metastases with a sensitivity and specificity of 100% and 88%, 
compared to bone scintigraphy combined with targeted X-rays with a sensitivity 
and specificity of 63% and 64%. However, the highest specificity of a 100% (at the 
cost of a lower sensitivity of 88%) was reported when bone scanning together with 
targeted X-rays and Mr imaging was performed. larger trials can possibly clarify 
what the best approach in clinical practice should be. noteworthy, limiting Mri 
to the axial skeleton will suffice as the probability of finding solitary metastases 
outside this area is negligible (34;35). New insights for DWI concerning skeletal 
metastases could possibly lead to even higher detection rates (figure 2) (36-38).
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figure 1: a 65 years old patient, with a Psa of 6.1. With transrectal ultrasound guided prostate biopsy this 
patient was staged as a t1c with a gleason score of 3+4 on histopathology. on the multi-parametric 
staging Mri, the axial t2-weighted image (a) showed extracapsular extension (ePe) (white arrows) in 
cancer suspicious region (csr) number 1. on the diffusion weighted imaging (DWi) derived apparent 
diffusion coefficient (ADC)-map (b) this csr (red circle) was also visible, which appeared to be a 
intermediate grade (4+3). the low grade lesions (3+4 and 3+3) 2 and 3 were not visible on the aDc map. 
on the dynamic contrast-enhanced Mr image (Dce-Mri) (ktrans) (c) two additional areas showed 
focal enhancement, csrs number 2 and 3 (white circles). the histopathologic slide (d) confirmed the 
presence of prostate cancer (Pca) in csrs 1,2, and 3, and the presence of ePe (red arrows).
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figure 2: a 70 years old patient with a rising Psa after brachytherapy. Bone scintigraphy (a) and 
conventional X-ray (b) revealed no skeletal metastases. Mr imaging (c) showed a suspicious region 
for a skeletal metastases (white arrow), which was followed up, and was even more obvious on (d) the 
second Mr imaging examination after 2 months (white arrow), suggesting progression of the metastases. 
a ct guided biopsy was performed (e, f) and revealed a Pca skeletal metastases (white arrows).
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Lymph node
ct and Mri demonstrate an equally poor performance in the detection of lymph 
node metastases from Pca, especially concerning sensitivity (39). for this reason, 
two other Mr techniques have been developed: Mr lymphography (which uses 
a lymph node-specific contrast agent, based on Ultra-small Superparamagnetic 
Particles of iron oxide (usPio)) and DWi-Mri (figure 3).
 in 1998, Bellin et al reported on the initial clinical experience with Mrl and 
found a perfect sensitivity of 100% at 80% specificity (40). In another prospective 
study with 334 lymph nodes in 80 patients, sensitivity and specificity were 90.5% 
and 97.8%, respectively (41). More recently, it has been shown that Mrl is 
significantly more accurate than Multi Detector-row CT (42, and that in 41% of 
Pca patients, Mrl can detect lymph node metastases outside the surgical area 
of routine Pelvic lymph node Dissection (43). although these results are very 
promising, Mrl has not yet become available for widespread clinical use, due to 
the lack of an FDA-approved lymph node-specific contrast agent.
 the added value of DWi compared to usPio-Mrl does not improve accuracy 
but rather reduces reading time (44). however, one study did report a good 
accuracy based on the apparent diffusion coefficient (ADC) map value alone, 
with a sensitivity of 86.0% and a specificity of 85.3% (45).
a b c
figure 3: a 59 years old patient with Pca and lymph node metastases. coronal t1- weighted gradient 
echo (gre) (a) 24 hour post ultra-small superparamagnetic Particles of iron oxide (usPio) injection 
showed 2 normal sized nodes (arrows). the right one is black (horizontal arrow), suggesting presence of 
ultra-small superparamagnetic Particles of iron oxide (usPio)-loaded macrophages, which indicates 
that this node is normal. the left one is gray (vertical arrow), due to the absence of usPio. fusion of t1-
gre image with t2*- weighted (sensitive to iron) image (orange) (b), and fusion of t1-gre image with 
DWi (b=600, orange) (c) respectively. on both images the node on the left side showed t2*-signal, and 
high diffusion signal due to absence of usPio contrast, thus indicating metastasis.
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voluMe MeasureMent
for focal therapy, merely localizing Pca is not enough. Determining cancer foci 
volume is of paramount importance for targeting this form of therapy. studies 
regarding this matter are few in number and not consistent (46-49). in 2002 the value 
of Mrsi in measuring tumour volume in nodules greater than 0.5 cm3 was assessed 
and researchers found that it was positively correlated with histopathologic tumour 
volume with a Pearson correlation coefficient of 0.59 (50). More recently, DCE-MRI 
and DWi have as well been investigated and some promising results have been 
presented (51;52).
aggressiveness
the gleason grading system remains one of the most effective prognostic 
factors in Pca (53). gleason score, Psa level, and clinical stage have a major 
role in therapy decision making. they have been associated with biochemical 
failure, local recurrences, and distant metastases such as skeletal and lymph 
node metastasis after prostatectomy or radiation therapy (54-58). since gleason 
scores of 3+4 - or lower - are associated with lower disease progression rates, and 
gleason scores of 4+3 - or higher - are associated with higher disease progression 
rates (59), a test differentiating between both is meaningful. 
 although studies reporting on association of gleason grade with Mr imaging 
are scarce (60), with DWI a significant negative correlation between Gleason 
grade and aDc values has been found (61-63). furthermore, choline plus 
creatine-to-citrate ratios determined by using Mrsi have also been correlated 
with Gleason grade (64;65). One study even reported on the correlation of signal 
intensities on t2-w imaging with gleason grade (66). More research needs to 
be done as regards to what role multi-parametric Mr imaging can play in the 
assessment of Pca aggressiveness.
recurrences 
Recurrence of local PCa
the majority of patients with Pca is either treated with radical prostatectomy 
(rP) or radiotherapy (rt). approximately 30% will experience recurrent disease 
(67). currently, Psa elevation after rP or rt is the best indicator of biologically 
active tumour (68;69). Whenever such an elevation of PSA has taken place, the 
main objective is to find out whether the increase in PSA is due to local or distant 
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recurrent disease. imaging is required as further detailed information about the 
site of recurrence is needed. 
 After RT the prostate will be characterized by a diffuse low signal (70;71). For this 
reason, t2-w imaging is less helpful in localizing recurrence of Pca. gadolinium-
based contrast agents are of added value. studies evaluating Dce-Mri after 
RT report sensitivities between 70%-74% and a specificities between 73%-85% 
(72;73). Subsequently, a targeted MR-guided biopsy can be performed (Figure 
4) (74). the incremental value of Mrsi in localizing Pca after rt has also shown 
to be useful (75;76). Although DWI after radiotherapy can be supportive (77;78), 
after rP it is of limited value because of surgical clips (left behind by the urologist 
during surgery) causing magnetic field inhomogeneities. After RP DCE-MRI and 
Mrsi provide promising results (figure 5) (79-81).
a
d
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e
figure 4: a 69 years old patient, with a Psa rise (25 ng/ml) after external radiation beam therapy. a 
multi-parametric Mri was performed. the t2-w image (a) showed no csr. Dce-Mri (ktrans) (b) showed 
csr number one (white circle), DWi derived aDc-map (c) showed restriction in another csr number 
2 (red circle). of both csr an Mr-guided biopsy was obtained (d + e) and histopathology revealed a 
leason 3+4.
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figure 5: a 71 years old patient with a Psa of 0.39 ng/ml after a radical prostatectomy in 2007. a multi-
parametric Mri, consisting of a t2-w image (a), a Dce-Mri (b) with a csr (white circle), a DWi derived 
aDc-map (c) with inhomogeneities of the magnetic field due to surgical clips (white arrows). A MR-
guided biopsy (d) of this csr revealed a Pca with a gleason score of 3+5.
coMputer aided diagnosis
computer assisted technologies have been developed to help interpret the often 
multi-dimensional and multi-parametric data. in mammographic detection of 
breast cancer such aids have been successfully developed and have become 
part of routine clinical work (82). applications to the prostate are emerging.
 two types of computer assisted technologies exist: computer aided detection 
(caD) and computer aided diagnosis (caDx). caD provides, fully automatically, 
feedback on zero or more locations containing malignant cancers. it is caD that 
has been used in mammographic screening, whereas caDx, often confused 
with CAD, only provides a probability of malignancy of a user identified lesion. 
caD and caDx both contain a supervised pattern recognition module trained 
on annotated cases. Although companies provide prostate MR specific tools with 
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the name caD in it, neither caD nor caDx is currently commercially available for 
prostate Mr.
 caDx research for prostate is still limited. the main focus in caDx is to have 
objective features or thresholds for the pattern recognition system of Pca. studies 
using simple raw image derived methods report lower aucs of 0.72 (83-85) than 
studies using quantitative features (AUCs of 0.81) (86;87). Combining quantitative 
features from all available sequences (multi-parametric Mr imaging) is currently 
lacking, but first attempts are promising (AUC of 0.89) (88;89). An important 
obstruction for prostate Mr caD and caDx, to become widely available, is the 
lack of standardized sequences and objective quantitative features of Pca.
furthermore, without evidence of effectiveness of caD or caDx in clinical 
situations clinical use should be avoided.
intra-prostatic high dose boosting with intensity-
Modulated radiotherapy
in the treatment of Pca, rt has evolved from the use of rectangular beams to 
3-dimensional (3D) conformal beams, and eventually to segmentation and dose 
intensity modulation of these beams known as iMrt. iMrt allows the radiation 
oncologist to plan a precise dose distribution in the targeted organ. Potentially 
this results in a high dose escalation in the targeted cancer foci (dominant 
intraprostatic lesion (Dil)), while lowering treatment induced toxicity to non-
cancerous prostate tissue and organs abut the prostate, and thus expectantly 
improving the therapeutic ratio (90-95). this is achieved by using an inverse 
treatment planning method consisting of defining the desired dose distribution to 
the target volume and dose restriction to uninvolved tissue or organs (96). 
 for such a treatment planning strategy a reliable imaging technique is an 
essential necessity. computed tomography (ct) is probably most frequently used 
as treatment planning technique. CT has some benefits over MRI as it is helpful in 
rt dose calculations, because of the accurate electron densities provided by it, 
and its deficit of geometric distortion. Some promising efforts have been made to 
overcome both matters concerning MRI (97;98). Still there is more work necessary 
in the consideration of performing focal high-dose Dil-iMrt planning with Mri 
alone. The faultiness of CT compared to MRI is that it lacks sufficient soft tissue 
contrast to precisely delineate the prostate gland, especially in the apex of the 
prostate, consequently overestimating prostate volume (99-102). furthermore, 
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CT struggles with significantly higher interobserver variability than MRI (101). In 
addition to all the foregoing, Mri as opposed to ct has the ability to localize the 
cancer foci in the prostate (see localization of Pca). eventually, with a precise 
dose delivery technique such as Dil-iMrt, one has to bear in mind that its success 
rate is highly dependent on the accurate delineation of the target volume.
 future developments will probably make it possible to use Mri directly in the 
treatment planning of rt. until then we need to combine both techniques and 
use all assets provided by both of them by the method of fusion. By using a gold 
marker-based 3D fusion of ct and Mri it is feasible to plan a safely delivered 
intraprostatic high radiation-dose Dil-iMrt, where a Dil volume for example can 
be defined by using DCE-MRI and MRSI (Figure 6 and 7) (92;103). With the help of 
special software programs merging of Mr and ct images can be realized with 
fusion inaccuracies with a mean of 1.1 mm at the border of the prostate (104). 
Other efforts in finding new fiducial markers for this fusion process have been 
made (105).
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figure 6: Dce-Mri and 1h-spectroscopic (Mrsi) results for a 71 years old patient with a Psa of 5.8 
ng/ml with biopsy proven Pca. axial t2-weighted Mr image (a) with decreased signal intensity in 
right peripheral zone (arrows), without evidence of capsular invasion. Dce-Mri results (b,c). start-of-
enhancement parameter (b) demonstrated earlier enhancement in part of low-signal-intensity lesion 
(arrows) compared with left peripheral zone. volume transfer constant (ktrans) (c) was elevated in low-
signal-intensity lesion (arrows) indicating tumour tissue. Mrsi (d) detected elevated choline and low 
citrate peaks in seven voxels. Blue box indicates voxel from which spectrum (fig. 6e) originated. 1h-Mri 
spectrum (e) from voxel in right peripheral zone. increased choline (cho) plus creatine (cr)/citrate (ci) 
ratio indicated prostate cancer. strongly interpolated (cho +cr)/ci map (f) was used to visualize Mrsi-
based tumour nodule.
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figure 7: Dominant intraprostatic lesion-intensity-modulated radiotherapy treatment volumes for same 
patient as in figure 6. Three-panel (transverse, sagittal, and coronal view) computed tomography 
treatment planning image: dominant intraprostatic lesion volume (red color wash) and prostate (black 
line) were delineated with margin of 5 and 7 mm, for planning target volume with prescription dose of 
90 gy (red line) and prescription dose of 70 gy (orange line), respectively. central gold marker indicated 
in yellow.
Mr guided biopsy and robotics 
cancer suspicious regions (csrs) seen on multi-parametric Mri can be targeted 
for biopsy. this can be done by either performing a trus-guided biopsy, a trus-Mr 
fusion guided biopsy, or an Mr-guided biopsy. no studies have been performed 
comparing these different biopsy methods. Mr-guided prostate biopsies have 
shown to improve cancer detection rate in subjects with an elevated Psa and 
repetitive negative trus-guided biopsies (106-108). 
 so far, the only commercially available Mr-guided prostate biopsy device 
is a manually adjustable standard for needle guide positioning (106;109). The 
radiologist has to adjust the needle guide into the direction of the region of 
interest by hand, based on Mr images (109). consequently, the patient has to 
be withdrawn from the scanner bore each time to adjust the direction of the 
needle guide. it is conceivable that during these time consuming manoeuvres, 
there is abundance of time for movement of the patient as well as movement 
of the prostate, possibly leading to less accuracy. furthermore, one can imagine 
that this procedure is unpleasant for the patient. 
 for these reasons Mr-compatible robots for transrectal prostate biopsy are 
being developed. Preliminary results found in phantom and patient feasibility 
studies are promising (110-114). in future studies robotics can for instance also 
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play an important role in guiding focal treatment of Pca. But before robot assisted 
Mri guided focal therapy can be realized further extensive research needs to be 
done.
conclusion
in conclusion, multi-parametric Mr imaging is a versatile, and promising 
technique. it appears to be the best available imaging technique at the 
moment in localizing, staging (primary as well as recurrent disease, and local as 
well as distant disease), determining aggressiveness, and volume of Pca. With 
this information guidance of focal therapy, iMrt and biopsy can be realized.
 However, larger study populations in multi-centre settings have to confirm 
these promising results. yet before such studies can be performed, more research 
is needed in order to achieve standardized imaging protocols regarding issues in 
obtaining data (e.g. b-values in DWi, t1-w or t2*-w in Dce-Mri, 1.5t vs. 3t, the use 
of an endorectal coil) and quantifying and determining objective parameters or 
thresholds (e.g. aDc values in DWi, calculating pharmacokinetic parameters in 
Dce-Mri ) for Pca. as a consequence, supportive techniques such as computer-
aided diagnosis can be developed further.
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abstract 
purpose
the purpose of this study was to compare the diagnostic performance of 3 tesla 
(3t), 3-dimensional (3D) Mr spectroscopic imaging (Mrsi) in the localization of 
prostate cancer (Pca) with and without the use of an endorectal coil (erc).
Materials and Methods
our prospective study was approved by the institutional review board, and 
written informed consent was obtained from all patients. Between october 2004 
and January 2006, 18 patients with histologically proven PCa on biopsy and 
scheduled for radical prostatectomy were included and underwent 3D-Mrsi 
with and without an erc. the prostate was divided into 14 regions of interest 
(ROIs). Four readers independently rated (on a five-point scale) their confidence 
that cancer was present in each of these ROIs. These findings were correlated 
with whole-mount prostatectomy specimens. areas under the receiver operating 
characteristic curve (auc) were determined. a difference with a P < 0.05 was 
considered significant.
results
a total of 504 rois were rated for the presence and absence of Pca. localization 
of PCa with MRSI with the use of an ERC had a significantly higher AUC (0.68) than 
Mrsi without the use of an erc (0.63) (P = .015). 
conclusion
The use of an ERC in 3D MRSI in localizing PCa at 3T slightly but significantly 
increased the localization performance compared to not using an erc.
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introduction
Prostate cancer (Pca) is the most commonly diagnosed non-cutaneous form 
of cancer in men and is the second largest cause of cancer related mortality in 
this population (1). like many cancers, Pca is treated most effectively if localized 
and staged correctly. thus, reliable knowledge of the location and spatial extent 
of the disease within and beyond the gland is crucial. 
 the most frequently used diagnostic tools in daily clinical practice (e.g. digital 
rectal examination (DRE), prostate specific antigen (PSA) level, and transrectal 
ultrasound (trus) guided biopsy) are often inaccurate or inadequate. Dre misses 
a substantial proportion of cancers, Psa alone cannot accurately stage an 
individual patient, and trus suffers from major sampling errors (2-6). 
 Magnetic resonance (Mr) imaging is a noninvasive examination, which can 
provide anatomical, functional, and metabolic information. Mr spectroscopic 
imaging (Mrsi), that generates metabolic spectra, has been investigated 
before for cancer localization. some promising results have been reported with 
sensitivities and specificities of 63-80% and 75-84%, respectively (7;8). In addition, 
Mrsi and Mr imaging are still evolving techniques where recent insights about 
new metabolic markers such as polyamines (9;10), and new approaches with 
dynamic contrast-enhanced and diffusion-weighted Mr imaging could further 
improve its localization ability (11-14) . 
 the use of an endorectal coil (erc) as an essential part of the optimal prostate 
Mr imaging protocol is still a matter of debate. the obvious advantage of using 
the erc is the increase in signal-to-noise ratio compared to non-erc Mr imaging. 
even though several authors have demonstrated the advantages of the use of 
such an ERC for localizing and staging PCa on T2-weighted MR imaging (15;16), 
the direct comparison between erc and non-erc Mr examinations has not 
been investigated for Pca localization with three-dimensional (3D) Mrsi. 
 We hypothesized that the use of an erc will increase the diagnostic 
performance of Mrsi in localizing Pca. therefore, the purpose of this study was to 
compare the diagnostic performance of 3 tesla (3t), 3D Mrsi in the localization 
of Pca with and without the use of an erc.
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Materials and Methods
Patients 
our prospective study was approved by the institutional review board, and written 
informed consent was obtained from all patients. During the time period in which 3D 
MRSI at 3T was firstly initiated and performed at our institution (between October 2004 
and January 2006), 18 consecutive patients with histologically proven PCa on biopsy 
and scheduled for radical prostatectomy were included and underwent 3D-Mrsi (at 
least three weeks after biopsy) with and without an erc. Patient characteristics were 
as follows: median age 66 years (range 56-75 years), median Psa 4.9 ng/ml (range 
3.6-24.6 ng/ml), median time between trus guided biopsy and Mr examination 
64 days (range 21-104 days), median time between Mr examination and radical 
prostatectomy 7 days (range 1-89 days), and median gleason score, based on 
prostatectomy specimens, 6.5 (range 5-9). exclusion criteria were previous hormonal 
therapy and contraindications to Mr imaging (e.g., cardiac pacemakers, intracranial 
clips, prior anorectal surgery). 
MR Imaging Protocol
Mr imaging of the prostate was performed using a 3t whole body Mr system 
(siemens trio tim, erlangen, germany) with the spine array and body array coil 
elements, with a total examination time of between 45-50 minutes. Bowel peristalsis 
was suppressed with an intramuscular injection of 1 mg of glucagon (glucagen, 
Novo Nordisk, Bagsvaerd, Denmark). At first, patients were imaged without the use 
of an erc according to the following Mr imaging protocol sequences: t2-weighted 
fast spin echo sequence in three orthogonal planes, with the field of view of the axial 
plane obtained perpendicular to rectal wall, (TR/TE, 3700/124 msec; field of view, 
220 x 220 mm; matrix size, 512 x 512; slice thickness, 4 mm; number of averages, 2; 
total acquisition time per plane, 4-5 minutes), followed by 3D 1h-Mrsi of the entire 
prostate with a point-resolved spectroscopy pulse sequence (15) (tr/te, 750/145 
msec; acquisition bandwith, 1250 Hz; voxel resolution, 7 x 7 x 7 mm; total acquisition 
time, approximately 9 minutes). 
 Subsequently, in the same patient an ERC was inserted rectally and filled with 40 
ml perfluorocarbon liquid (Fomblin, Solvay-Solexis, Milan, Italy). After a quick series 
of images obtained to depict erc position and erc adjustment if necessary, a t2-
weighted fast spin echo sequence in three planes (TR/TE, 5000/153; field of view, 200 
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x 100 mm; matrix size, 768 x 384; slice thickness, 2.5 mm; number of averages, 1; total 
acquisition time per plane, 2-3 minutes) was obtained, with the field of view of the 
axial plane obtained perpendicular to rectal wall, followed by 3D 1h -Mrsi (tr/te, 
750/145 msec; acquisition bandwith, 1250 Hz; voxel resolution, 6 x 6 x 6 mm; total 
acquisition time, approximately 9 minutes).
Data Postprocessing
semi-automatic postprocessing of all voxels within the prostate was performed with a 
software work-in-process package (Metabolite report, siemens, erlangen, germany). 
a basic set of simulated complex model signals of choline, creatine, and citrate 
was fitted to the time domain signals of the voxels after a frequency shift, residual 
water removal, and remodeling of the first five data points to handle baseline 
artifacts. The amplitudes of the individually fitted signals were used to calculate the 
(choline+creatine)-to-citrate ratio (cc/c) and the choline-to-creatine ratio (c/c). a 
similar approach has been used before (17).
Scoring and Evaluation of Data
all Mrsi datasets were evaluated overlaid on the t2-weighted datasets. the prostate 
was divided into 14 regions of interest (rois) (figure 1). the t2-weighted images were 
only used for transfer of the 14 rois to the Mrsi data and subsequently correlating 
this with pathology. four readers (reader i (radiologist), ii (radiologist), iii (radiologist), 
and iv (spectroscopist) with 0, 4, 6, and 8 years of experience in Mrsi data evaluation, 
respectively) independently rated cancer presence in each of these ROIs on a five-point 
scale, using a standardized scoring system (18). this scale was based on the choline-
creatine-to-citrate (cc/c) and choline-to-creatine (c/c) ratios for the peripheral zone 
and the central gland determined before by scheenen et al. (19) (table 1). 
 all datasets were anonymized, and readers were blinded to all clinical parameters. 
they were only aware of the fact that all patients were histopathologically diagnosed 
with Pca. first, all Mrsi examinations without the erc were rated. for each roi, all 
spectra were read and interpreted and the final score for that ROI was based on the 
highest cc/c present within the roi, and adjusted based on the c/c ratio for the 
corresponding voxel (table 1). second, after a period of 4 weeks, during a different 
reading session, Mrsi with the erc were rated likewise. readers were allowed to rate 
ROIs as non-rateable if ratios were not reliably fitted due to low signal-to-noise ratios of 
the metabolite spectra (more than 50% of the voxels within a certain roi).
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figure 1: a schematic overview of the 14 regions of interest in which the prostate was divided into.
table 1
five-point scale
Score and Score definition pz cc/c ratio cg cc/c ratio c/c ratio adjustment
If C/C ratio ≥2, then: adjust 3 
and 2 into 4. 
if c/c ratio < 2, then: adjust 5 
into 4 and 4 into 3.
1: Definitely benign tissue ≤0.34 ≤0.48
2: Probably benign tissue >0.35-0.46 >0.49-0.62
3: Possibly malignant tissue >0.47-0.58 >0.63-0.76
4: Probably malignant tissue >0.59-0.70 >0.77-0.90
5: Definitely malignant tissue ≥0.71 ≥0.91
source: reference (17). Pz= peripheral zone, cg= central gland, cc/c = choline-creatine-to-citrate, 
c/c = choline-to-creatine.
Histopathological Analysis
Prostatectomy specimens were fixed overnight in 10% neutral buffered 
formaldehyde and coated with india ink. these prostatectomy specimens were 
sliced at 4-mm intervals at a plane parallel to the axial t2-weighted images 
(perpendicular to rectal wall). All slices were routinely embedded in paraffin. 
tissue sections of 5 µm thickness were prepared from the slices and stained with 
hematoxylin-eosin. a single genitourinary histopathologist (c.a.h. van de k.) with 
18 years of experience who was blinded to the Mr imaging results determined 
the exact localization, extent, gleason score, and volume of each cancer focus.
Data Analysis
After evaluating and scoring all MRSI data, one Spectroscopist (T.W.J.S.) and two 
of the Radiologists (J.J.F. and D.Y.) in consensus transferred the histopathologic 
evaluation (standard of reference) of the prostatectomy specimens to the 
14-segment prostate roi-scheme. this transfer was realized by matching the 
pathological slice to the level of the t2-weighted images by its location between 
the apex and the base of the prostate. subsequently, landmarks such as benign 
57
c
hapter 3
M
rsi w
ith and
 w
ithout erc
prostatic hyperplasia nodules and the urethra were used to match cancer foci to 
their corresponding rois. the t2-weighted images were only used for correlating 
pathology to the cancer region relative to the 14-segment roi-scheme. a roi 
was considered true-positive if cancer was present and if this cancer focus was 
0.5 cm³ or larger in volume (20). all smaller cancer foci were excluded from further 
analysis. Each of the 14 ROIs for every prostate were classified as containing 
either cancer or healthy tissue.
Statistical Analysis
For statistical analysis (SPSS version 16.0), the sensitivity, specificity, negative 
predictive value (nPv) and positive predictive value (PPv) were calculated by 
dichotomizing (cut-off point of 3 and above was considered malignant) the 
readings. areas under the receiver operating characteristic curve (auc) and 
comparison between these aucs were determined by using an roi-roc analysis 
(21) with a bootstrap estimation of diagnostic accuracy (22) and a Bonferroni 
correction. these statistical methods have been used before in studies that 
collected data according to the ROI paradigm (8;15). All P values reported were 
derived at one-sided tests. P values of .05 or less were considered significant.
results 
eighteen patients were included. a total of 504 rois (18 patients with 14 rois 
each, 252 rois with and 252 rois without erc) were rated for the presence and 
absence of Pca (figure 2). from the histopathologic standard of reference, 
81/252 (32%) rois were assigned as containing Pca. thirty-one of these 81 
rois containing Pca, were excluded due to low cancer volume (<0.5 cm³). 
Of the remaining 50 ROIs classified as containing PCa, 72% (36/50) comprised 
peripheral zone cancers while 28% (14/50) comprised central gland cancers. 
these remaining cancer foci had a median volume of 1.1 cm³ (range 0.5-12.9 
cm³) (figure 3).
 Overall, there were significantly more ROIs non-rateable on MRSI with ERC, 14% 
(146/1008), than without erc, 12% (121/1008), (P = .007) for all readers together 
(table 2).
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Descriptive statistics of Pca localization with and without an erc per reader 
were summarized in table 3. for the more experienced readers (i.e. readers ii, iii, 
and IV) MRSI with an ERC had a high specificity (82%-92%), but a low sensitivity 
(20%-57%). for the novice reader (reader i), Mrsi with the use of an erc had a 
high sensitivity (80%) and a low specificity (34%). For all readers, the negative 
predictive values were high (82%-89%) while the positive predictive values were 
low (20%-45%) for both imaging with and without erc.
 the aucs increased with the experience of the reader (table 4). the most 
experienced reader (reader iv) had the highest auc (0.72) for localization of 
Pca with Mrsi with an erc. overall aucs were calculated for reader ii, iii, and iv 
together. Localization of PCa with MRSI with the use of an ERC had a significantly 
higher auc (0.68) than Mrsi without the use of an erc (0.63) (P = .015) (figure 4). 
a b
d e
d
figure 2: Presentation of how readers were able to evaluate and score the data in one view. Mr images 
of a 73-year-old man with a Psa of 5.0 ng/ml. from left to right: overlaid on transverse t2-weighted 
multiple-spin-echo image (TR/TE 3700/124) spectral fits (a), choline+creatine-to-citrate ratio (cc/c) 
(b),choline-to-creatine ratio (c/c) (c), and voxel number (d). Magnified view of metabolite spectrum 
of the voxel at the red arrow, which had the highest cc/c ratio of region of interest (roi) number 10. 
Measured spectrum (white line), overlaid with fit (red line), and residual between data and fit (green 
line) (e). this voxel had a cc/c ratio of 0.83 in the peripheral zone of the prostate. the c/c ratio was 1.06 
so, according to Table 1 this voxel, representing segment 10, was classified as probably malignant tissue. 
histopathology revealed prostate cancer in this segment with a gleason score of 3+3.
59
c
hapter 3
M
rsi w
ith and
 w
ithout erc
0
1
2
3
4
5
6
7
8
9
0.5-1.0 1.1-1.5 1.6-2.0 2.1-2.5 2.6-3.0 10.0-15.0
n
um
be
r
volume cm³
figure 3: cancer foci volume distribution on histopathology. Median tumor volume 1.1 cm3, range 0.5-
12.9 cm3.
table 2
number of non-rateable rois
Mrsi - Mrsi +
reader i 3%    (6/252) 0%    
reader ii 18%  (50/252) 22% (62/252)
reader iii 8%    (20/252) 14% (36/252)
reader iv 18%  (45/252) 19% (48/252)
Mrsi - = Mr spectroscopic imaging without an endorectal coil, Mrsi + = Mrsi with an endorectal coil. 
P = .007.
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table 3
diagnostic performance in localizing prostate cancer with Mrsi with and without an erc
Mrsi - Mrsi +
sensitivity Specificity npv ppv sensitivity Specificity npv ppv
reader i 65% 
(26/40)
43%
(76/178)
84%
(76/90)
20%
(26/128)
80%
(33/41)
34%
(62/183)
89%
(62/70)
21%
(33/154)
reader ii 30% 
(13/43)
88% 
(164/186)
85% 
(164/194)
37%
(13/35)
20%
(9/44)
92% 
(159/173)
82%
(159/194)
39% 
(9/23)
reader iii 33% 
(14/43)
70% 
(133/189)
82% 
(133/162)
20% 
(14/70)
32% 
(13/41)
87% 
(153/175)
85%
(153/181)
37% 
(13/35)
reader iv 42% 
(18/43)
74% 
(122/164)
83% 
(122/147)
30% 
(18/60)
57%
(24/46)
82% 
(129/158)
85% 
(129/151)
45%
(24/53)
Mrsi - = Mr spectroscopic imaging without endorectal coil, Mrsi + = Mrsi with endorectal coil.
table 4
auc’s for localizing prostate cancer with Mrsi with and without an erc
Mrsi -
auc
Mrsi +
auc
p value
reader i 0.55 0.61 .047*
reader ii 0.62 0.65 .151
reader iii 0.59 0.68 .014*
reader iv 0.67 0.72 .056
overall (ii, iii, and iv) 0.63 0.68 .015*
Mrsi - = Mr spectroscopic imaging without endorectal coil, Mrsi + = Mrsi with endorectal coil. 
* = considered significant.
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auc 0.68 (95% ci 
0.59−0.76)
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auc 0.72 (95% ci 
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figure 4: roi-roc curves for the experienced readers for localizing prostate cancer with Mr 
spectroscopic imaging without an endorectal coil (Mrsi -) (a), and with an endorectal coil (Mrsi +) (b).
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discussion 
In the localization of PCa with MRSI at 3T, the use of an ERC provided a significantly 
(P = .015) higher auc (0.68) for experienced readers compared with not using an 
erc (auc 0.63) (figure 4). Despite the fact that this difference was statistically 
significant, such a small increase in the AUC should make one think whether using 
the erc is worth the effort, cost and patient discomfort. When calculating the 
general aucs for all readers together we excluded the results from reader i. this 
was done because of the vastly different level of experience of this reader (no 
experience) for evaluating Mrsi data compared to the other three readers (at 
least 4 years of experience), as evidenced by the contrasting descriptive statistics 
compared to the other readers. All other readers had high specificities and low 
sensitivities, whereas reader I had a high sensitivity and a low specificity. 
 in general the aucs for localization with or without the use of an erc were low 
compared to earlier published studies in localizing PCa with MR imaging (7;8). 
only one previously published multi-centre study on the localization of Pca with 
Mrsi at 1.5t presented even lower aucs compared to our study (23). some of 
their main arguments for such low aucs, such as low image quality and limited 
experience in obtaining data are somewhat shared by us. the results of our study 
were based partly on Mrsi data that were obtained in 2004 when we had just 
commenced acquiring Mrsi on a 3t system. the high number of non-rateable 
rois (table 2) clearly illustrated this limited experience in 3t data acquisition. With 
matured technology (improved shimming), better coils and more experienced 
technicians, current data quality in clinical practice is expected to be improved, 
possibly resulting in an increased signal to-noise-ratio of the spectra and less non-
rateable regions in the prostate. furthermore, in our study the experience level 
of the reader was also shown to be of influence by the fact that the highest AUC 
(0.72) was achieved by the most experienced reader (reader iv). altogether 
this emphasizes the importance of experience in both acquiring and reading 
spectroscopic data. future studies should therefore focus on training radiologists 
to read spectroscopic data (with possible pitfalls such as false positives due to 
high choline signals from seminal vesicles, and unreliable fits due to low signal-to-
noise ratios) as well as technicians in obtaining high image quality data. 
 nonetheless, it is important to note that the main purpose of our study was to 
compare the performance of Mrsi in the localization of Pca with and without an 
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erc. the low overall aucs did not interfere with our conclusion that the use of the 
ERC only marginally, but significantly, improves localization performance. 
 More rois were judged non-rateable on Mrsi with the use of an erc than in 
the set of images without the use of an erc. in one other study (15), the authors 
established that there was a higher presence of motion artefacts in the erc 
group (compared to the non-erc group) which could explain the higher amount 
of non-rateable rois in the erc group (compared to the non-erc group) in our 
study. It is very difficult to assess motion during the MRSI measurements. As the 
Mrsi part of the protocol is performed after t2w Mri in three directions (larger 
time gap from pre-examination glucagon injection), and takes longer than one 
t2w series alone, motion during Mrsi cannot be ruled out and may indeed be a 
source of error. even the absence of these artefacts on t2w Mri cannot rule out 
motion during Mrsi. also, this difference in non-rateable rois in favour of the erc 
group could be accounted for by decreased signal-to-noise ratio at distances 
further away from the coil, in the ventral part of the prostate. 
 limitations of this study were initially, the low number of patients included, 
although this was partially compensated for by the 14 rois per prostate that were 
used and the multiple number of readers that were involved. second, poor snr 
and therefore the high number of non-rateable rois in these patients, because 
of this being the first patient cohort. Third, in this study we did not use T1-weighted 
images to assess the amount of haemorrhage after biopsy in the prostate gland. 
instead, to diminish this haemorrhage effect as much as possible, the time 
between biopsy and Mr examination was kept to a minimum of three weeks 
(24;25). Worth noting, any still existing haemorrhage effect would have affected 
the endorectal group as well as the non-endorectal group equally. fourth, the 
readers rating these data were able to see which set of images concerned the 
Mrsi data with the use of an erc as well as without the use of an erc. ideally, 
data in comparative studies should be presented in a blinded fashion. Blinding 
the use of an ERC is problematic, because it is very difficult to hide the increased 
snr, especially at the dorsal aspect of the prostate, and the deformed prostate/
rectum from a good radiologist or spectroscopist. 
 in conclusion, the use of an erc in 3D Mrsi in localizing Pca at 3t slightly but 
significantly increased the localization performance compared to not using an 
erc.
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abstract 
purpose
the objective of this study was to assess the feasibility of the combination of Mr-
guided biopsy (MrgB) and diagnostic 3t magnetic resonance (Mr) imaging in 
the localization of local recurrence of Pca after external beam radiation therapy 
(eBrt).
Materials and Methods
twenty-four consecutive men with biochemical failure suspected of local 
recurrence after initial eBrt were prospectively enrolled in this study. all patients 
underwent a diagnostic 3t Mr examination of the prostate. t2-weighted and 
dynamic contrast-enhanced Mr images (Dce-Mri) were acquired. two 
radiologists evaluated the Mr images in consensus for tumour suspicious regions 
(tsrs) for local recurrence. subsequently, these tsrs were biopsied under Mr-
guidance and histopathologically evaluated for the presence of recurrent Pca. 
Descriptive statistical analysis was applied.
results
tissue sampling was successful in all patients and all tsrs. the positive predictive 
value (PPv) on a per patient basis was 75% (15/20) and on a per tsr basis 68% 
(26/38). the median number of biopsies taken per patient was 3 and the duration 
of an MrgB session was 31 minutes. no intervention related complications 
occurred.
conclusions
the combination of MrgB and diagnostic Mr imaging of the prostate was a 
feasible technique to localize Pca recurrence after eBrt using a low number of 
cores in a clinically acceptable time.
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introduction
approximately 30% of the patients diagnosed with prostate cancer (Pca) are 
treated with external-beam radiation therapy (EBRT) as initial definitive treatment (1). 
of these patients, between 20 to 60% develop biochemical failure (2). Biochemical 
failure is considered to represent cancer recurrence (3) and correlates well with 
clinical progression as evidenced by local clinical control rates after 5 years in 
patients with and without biochemical failure of 86% and 99%, respectively (4).
 The diagnosis of recurrent PCa entails a prostate specific antigen (PSA) test, digital 
rectal examination (Dre), transrectal ultrasound (trus)-guided prostate biopsy and a 
bone scan. However, each of these diagnostic tools have definite shortcomings (5).
the Psa nadir, Psa half-life, time interval from treatment to Psa nadir, and Psa 
doubling time are all associated with both clinical and biochemical failure (6). yet, 
there is no absolute cut-off value to accurately discriminate on an individual basis, 
between local recurrence and distant metastases (7).
 Diagnosing local recurrence after eBrt by Dre is challenging due to radiation-
induced fibrosis and shrinkage of the prostate, whereas the sensitivity and specificity 
of trus after radiotherapy was found to be 49% and 57%, respectively (8).
 Magnetic resonance (Mr) imaging of the prostate is a well established 
modality for accurately localizing Pca. evaluation of the radiated prostate gland 
is restricted because of treatment-induced changes, resulting in homogeneously 
low signal on t2-w images (9, 10). hence, Mr imaging of the prostate after eBrt is 
much more challenging. functional imaging techniques, like dynamic contrast-
enhanced Mr imaging (Dce-Mri) (11, 12), diffusion weighted-imaging and proton 
Mr spectroscopy can improve the accuracy of localizing recurrence after eBrt 
(13-15). this diagnostic information can be used for directing biopsies to tumour 
suspicious regions (tsrs). thus far, trus is the most widely used imaging modality 
and systematic sextant trus-guided biopsy is considered the gold standard for 
histological assessment of a local recurrence, with a positive predictive value 
(PPv) of only 27% (8). however, this may be improved by Dce-Mri with a PPv 
of 46%-78% (11, 12). to our knowledge there are no studies available on 3t Mr-
guided biopsy (MrgB) in the localization of local recurrence of Pca after eBrt. 
 the purpose of our study was to assess the feasibility of the combination of 
MrgB and diagnostic 3t Mr imaging in the localization of local recurrence of 
Pca after eBrt.
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Materials and Methods
Patients
this study was approved by the ethics review board of our institution and informed 
consent was obtained.
 from october 2006 to March 2009, 24 consecutive patients (median age 
70 years; range 60-83) with biochemical failure (using the ASTRO definition of 3 
consecutive rises in Psa after reaching Psa nadir) after initial eBrt were enrolled 
in this prospective study. Patients were referred for Mr imaging of the prostate 
followed by MrgB. exclusion criteria were contraindications to Mr imaging 
(eg, cardiac pacemakers, intracranial clips). the pre- and post-radiotherapy 
characteristics of the patients are given in table 1. 
table 1. patient characteristics
characteristic datum (range) no. of missing data
Median age (yr) 70 (60-83)
preradiotherapy pathologic stage*
t1
t2
t3
3
4
13
Median preradiotherapy gleason score 7 (5-9) 2
Median preradiotherapy psa (ng/ml) 15.6 (6.1-96.0) 1
Median radiation therapy dose (gy) 67.5 (66.0-78.0) 3
no. of patients who received hormonal 
therapy
15
Median psa nadir (ng/ml) 0.26 (0.0-6.3)
Median psa level (ng/ml) prior to Mr imaging 4.4 (1.1-13.4)
Median time (yr) between radiation therapy 
completion and Mr examination
4.4 (1.1-13.4)
Median time (wk) between Mr examination 
and biopsy
4.1 (1.3-10.00)
* Data are numbers of men (n=20) with the given cancer stages.
MR Imaging protocol
Mr imaging of the prostate was performed using a 3t Mr scanner (siemens trio tim, 
erlangen, germany) with the use of an endorectal coil (erc) (Medrad, Pittsburgh, 
U.S.A) and a pelvic phased array coil. The endorectal coil was inserted and filled 
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with either a 40 ml perfluorocarbon or water preparation (FOMBLIN, Solvay-
solexis, Milan, italy). Peristalsis was suppressed with an intravenous injection of 
20 mg butylscopolaminebromide (BuscoPan, Boehringer-ingelheim, ingelheim, 
germany), intramuscular injection of 20 mg butylscopolaminebromide and 1 mg 
of glucagon (glucagen, nordisk, gentofte, Denmark).
 the imaging protocol included the following sequences: t2-weighted turbo 
spin echo sequences were acquired (TR 4260 ms/ TE 99 ms; flip angle 120; 3 mm 
slice thickness; echo train length 15; 180 x 90 mm field of view and 448 x 448 
matrix; voxel size 0.2 mm x 0.4 mm x 3 mm) in axial, coronal and sagittal planes. A 
3-dimensional (3D) T1-weighted gradient echo sequence (TR 4.90 ms/ TE 2.45 ms; 
flip angle, 10; 176 slices per 3D slab; 0.9 mm slice thickness; 288 x 288 field of view 
and 320 x 320 matrix; voxel size 0.9 mm x 0.9 mm x 0.9 mm) was used to assess 
lymph node and skeletal status. finally, an axial 3D t1-weighted gradient echo 
sequence (TR 800 ms/ TE 1.47 ms; flip angle, 14; 3 mm slice thickness; field of view 
230 x 230 and 128 x 128 matrix; voxel size 1.8 mm x 1.8 mm x 3 mm) was used to 
obtain proton-density images, with the same positioning angle and centre as 
the axial t2-weighted sequence (to allow calculation of the relative gadolinium 
chelate concentration curves), followed by 3D t1-weighted spoiled gradient-
echo images (TR 38 ms/ TE 1.35 ms; flip angle, 14; 10 transverse partitions on a 3D 
slab; 3 mm section thickness; 230 x 230 mm field of view; 128 x 128 matrix; voxel 
size 1.8 mm x 1.8 mm x 3 mm; GRAPPA parallel imaging factor 2; 2.5s temporal 
resolution; and 2 minutes 30 seconds acquisition time) acquired during an 
intravenous bolus injection of a paramagnetic gadolinium chelate—0.1 mmol of 
gadopentetatedimeglumine (DotareM, guerbet, Paris, france) per kilogram of 
body weight. This was administered with a power injector (Spectris; Medrad) at 
2.5 ml/sec and followed by a 20-ml saline flush.
MR Data Analysis
the prostate images of all patients were read in consensus by two radiologists 
with respectively two and five years of experience in prostate MR imaging. 
Functional dynamic imaging parameters were estimated from a fitted general 
bi-exponential signal intensity model for each Mr signal enhancement–time 
curve, as described previously (16, 17). the pharmacokinetic parameters (ktrans, 
ve, kep, and Washout) were computed using the standard two-compartment 
model (18) and the arterial input function was estimated using the reference 
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tissue method (19) and automated per-patient calibration (20). finally, these 
parameters were projected as colour overlay maps over the t2-weighted images. 
this patented procedure (21) for calculating pharmacokinetic parameters is 
being used in multiple centres. For the first two patients lesions were identified as 
suspicious purely if a focally enhancing region with Dce-Mri was seen irrespective 
of the degree of enhancement. to determine if regions enhancing in the prostate 
were representing tumour, we applied a lesion directed biopsy approach. to 
establish a “cut-off” in the colour coding of the pharmacokinetic maps we used 
the “normal” regions of these two patients as a cut-off for future colour coding. 
Above this “normal” threshold, radiologists then defined suspicious regions as 
focally enhancing spots shown on the colour maps. the criterion for tsrs on Dce-
Mri in the peripheral zone, the central gland and the seminal vesicles was a 
cut-off value of 3.5 (minute-1) for Ktrans and -0.225 [AU] for washout. The criterion 
for tsrs on t2-weighted Mr images was a low signal-intensity region within the 
prostate.
 Per patient, the t2-w images were evaluated for tsrs individually and in colour 
overlay (Dce-Mri). to locate the tsrs the prostate was divided into 22 different 
axial and sagittal segments, in order to make a 3D spatial position estimation of 
the identified TSRs which was used during the second MRGB-session. A similar 
translation technique was described before by hambrock et al. (22).
MR-guided biopsy
after the initial tumour localization Mr examination (median time between biopsy 
and initial localization MRI was 4.1 weeks; range 1.3-10.0), patients underwent an 
MrgB using an Mr-compatible biopsy device (invivo, schwerin, germany) at 
3T. All patients received oral ciprofloxacin 500 mg (CIPROXIN, Bayer, Leverkusen, 
germany) the evening before, on the morning of the biopsy and 6 hours post 
biopsy.
 relocation of the tsrs (by using the 3D spatial position estimation) determined 
during the first MR imaging localization was done by obtaining T2-weighted 
anatomical images in the axial direction. Prostate biopsies were performed with 
the patient in prone position and a needle guider inserted rectally which was 
attached to the arm of the biopsy device. the needle guider was pointed towards 
the tsr before obtaining the biopsy specimen (22). all biopsies were supervised by 
one experienced radiologist (4 years of experience) with MrgB of the prostate.
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Histopathology
Samples were subsequently processed by a routine fixation in 10% buffered 
formalin, embedded in paraffin, stained with hematoxylin-eosin, before being 
evaluated by an experienced genitourinary pathologist (18 years experience 
of PCa histopathology) for the presence of tumour. The biopsies were classified 
as negative if there was no evidence of carcinoma or residual indeterminate 
carcinoma with severe treatment effect, defined as isolated tumour cells or 
poorly formed glands with abundant clear or vacuolated cytoplasm. all positive 
biopsies were assigned a gleason score. 
Statistical analysis
Descriptive statistical analysis was applied. the positive predictive value (PPv) 
of tsrs seen on Mr images was calculated. the patient characteristics (median 
and range) were calculated by using sPss 16.0.
results 
three patients with contraindications to an erc (e.g., anorectal surgery, 
inflammatory bowel disease) were scanned with a pelvic phased array coil only.
Metastatic disease was evident on Mr imaging in 4 out of 24 patients. one 
patient had multiple low signal intensity areas in the left iliac and sacral bone 
and multiple enlarged lymph nodes (diameter greater than 10 mm) next to the 
right internal iliac artery. two patients had multiple enlarged lymph nodes next to 
the right internal iliac artery. one patient had multiple areas with focal low signal 
intensities in the body of l4, the right acetabulum and in the right anterior superior 
iliac spine. these patients received hormonal therapy and were excluded in the 
further analysis. 
 In the remaining 20 patients, a total of 38 TSRs were identified on combined T2-
weighted and Dce-Mri and subsequently biopsied with MrgB. all tsrs that were 
identified on T2-weighted imaging were also identified on DCE-MRI. With DCE-MRI 8 
TSRs, in 5 patients, were identified that were not identified on T2-weighted imaging. 
one patient had a hyperintense region compared to uninvolved prostate tissue as 
tsr on t2-weighted Mr imaging and increased permeability on Dce-Mri (figure 1), 
which turned out to be recurrent Pca on histological examination.
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Median MrgB time was 31 minutes (range 18-47) per patient and a median of 3 
biopsy cores per patient (range 2-5) was obtained. Median number of biopsies 
per tsr was 2 (range 1-4). the MrgBs were tolerated well and no procedure 
related complications occurred. tissue sampling was successful in all patients 
and tsrs.
 histologically proven local recurrence was evident in 15 patients (figure 
2). these patients were either treated with salvage cryosurgery (5 patients), 
salvage prostatectomy (1 patient), wait and see (1 patient), hormonal therapy 
(2 patients), were lost to follow up (4 patients), or died (2 patients). of the 38 
different TSRs identified on MR imaging, 26 contained histologically proven 
recurrence (68%), 8 revealed radiotherapy induced atypia in preexisting glands 
(21%), 1 contained residual indeterminate Pca with severe radiation changes 
(3%) and the remaining 3 contained fibrosis (8%). 
 the PPv of MrgB for detecting local recurrence on a per patient basis and per 
TSR basis was 75% (15/20) and 68% (26/38), respectively. There was no significant 
difference of the PPv when peripheral, central gland and seminal vesicles were 
considered separate and also the use of a pelvic phased array coil only had no 
influence on these results. Gleason score 10 was present in 2/26 (8%), Gleason 
score 9 in 8/26 (31%), gleason score 8 in 3/26 (12%), gleason score 7 in 9/26 (35%) 
and gleason score 6 in 4/26 (15%) tsrs.
 the site of recurrence within the prostate was present in the apical region in 
6 out of 26 tsrs, in the apex-mid in 5, in the mid in 9, in the mid-base in 3, in the 
base in 1 and in the seminal vesicle in 2 TSRs. The local recurrence was identified 
in the peripheral zone in 19 out of 26 (73%) tsrs and in the central gland in 7 of 26 
(27%) tsrs.
 Three of the five patients with negative histology received hormonal therapy, 
one underwent salvage cryosurgery and one underwent a follow up Mr 
examination. The patient with the follow up MR had unchanged MR findings in 
combination with a declining PSA (PSA during the first MR examination was 6.4 
ng/ml and during the follow up Mr imaging it was 3.7 ng/ml).
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a b c
figure 1: Mr images obtained from a 70 year old man with a tsr seen in the right ventral part in the 
mid-prostate, with a Psa of 0,4 ng/ml. the t2-weighted images showed a hyperintense tsr in the right 
ventral part in the mid-prostate (arrow) (a), also on Dce-Mri there was a tsr (high ktrans) visible (arrow) 
(b). During a second session, an MrgB was performed, the needle guider was pointed towards the tsr 
in axial (true-fisP image) (c) plane and subsequently biopsied. histopathology revealed a gleason 9 
prostate cancer recurrence.
a b c
figure 2: Mr images obtained from a 68 year old man with a tumor suspicious region (tsr) seen in the 
right peripheral zone at the apex-mid, with a Psa of 2,1 ng/ml. the t2-weighted images showed a 
diffuse low signal intensity of the entire prostate and no tsr was detectable (a), however on dynamic 
contrast-enhanced Mr imaging (Dce-Mri) there was a tsr (high ktrans) visible (arrow) (b). During a 
second session, an MrgB was performed, by pointing the needle guider towards the tsr in axial (true-
fisP image) (c) plane and subsequently biopsied. histopathology revealed a gleason 7 prostate cancer 
recurrence.
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discussion 
results of our study show that local recurrence after eBrt could be localized 
with the combination of MrgB and diagnostic Mr imaging in a substantial 
proportion of patients (PPv of 68% and 75% on a per tsr and a per patient basis, 
respectively). With a median intervention time of 31 minutes, and no procedure 
related complications, MrgB can be considered a feasible method in localizing 
local Pca recurrence following eBrt. 
 MrgB was not able to assess the effect of false negatives i.e. areas of 
prostate cancer which did not enhance, because of the relative time-consuming 
character of this procedure. however, previous studies that have used six core 
trus-guided biopsy as the standard of reference in localizing radiation therapy 
recurrence, including from regions that did not enhance on Dce-Mri, have 
shown that the negative predictive value of this technique is between 78%-95% 
(11,12). undoubtedly six core trus-guided biopsies have many limitations when 
used as the gold standard (e.g. high false negatives and underestimating of true 
gleason score). Which probably means that these negative predictive values 
of the above mentioned studies are somewhat overrated. correlating Dce-Mri 
with radical prostatectomy samples would be the best option and should be 
the next step in correlating recurrent disease seen on Dce-Mri. nonetheless, 
when selecting patients with prostate cancer recurrence the mostly followed 
treatment strategy is still some form of whole-gland salvage therapy. hence, 
false negatives are less of a problem. Merely detecting a recurrence, rather 
than mapping the recurrent tumour, will suffice for this particular group of 
patients. thus, only biopsying tsrs seen on Dce-Mri should be considered as an 
advantage rather than a disadvantage of MrgB biopsies. MrgB is capable of 
detecting a recurrence with only three biopsies per patient omitting trus biopsy 
core schemes (with a positive predictive value of 27% (8)) that use between 6-12 
cores per patient. consequently, it may lead to higher patient satisfaction. 
 the main advantage of trus-guided biopsy over 3t Dce-MrgB is that the 
expertise and the technique itself are more generally available in routine clinical 
practice. Probably, performing Mr-trus fusion for targeted biopsies by combining 
the high spatial resolution of Mr imaging with the wide-spread availability of trus is 
the most optimal strategy as evidenced by promising results in two different studies 
(23, 24). however, MrgB has the advantage of being directed towards tsrs using 
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the same imaging modality used for localization. this way spatial misregistration 
between Mr imaging and the biopsy core can be reduced to a minimum, which 
probably makes it a more precise method. unfortunately, randomized controlled 
trials comparing MrgB, trus-guided biopsy and Mr-trus fusion are not available 
yet.
 future studies should focus on inclusion of a larger number of patients and in 
order to improve the reproducibility of quantitative pharmacokinetic parameters 
(25) as well as to limit the subjectiveness of reader evaluation an automated per-
patient arterial input function estimation which was shown in a recent publication 
to be superior to fixed input models (20) is more preferred. 
 the widely known and accepted criterion for prostate cancer on t2-weighted 
Mr imaging, a region of low signal intensity, was used by us for localizing 
recurrence of PCa. It is interesting to note that we had a specific case with a 
hyperintense region compared to surrounding prostate tissue as a tsr which 
was confirmed on histological evaluation as PCa recurrence. This indicates that 
after eBrt a recurrence can also have a hyperintense character compared 
to surrounding prostate tissue on t2-weighted Mr imaging. furthermore, future 
studies may include other functional Mr imaging techniques such as diffusion 
weighted imaging (26) and Mr spectroscopy in guiding MrgB after eBrt. this 
may lead to a higher detection rate with a minimum number of biopsy cores.
 limitations of our study are related to the relatively small number of patients 
included and the incomplete data concerning patient characteristics, which 
was due to patient referral from outside our university hospital. in our study, we 
did not have any patient with a negative Dce-Mri on local prostate level. in other 
words, each patient we imaged had at least one tsr in the prostate detected 
with Dce-Mri. this can be interpreted as a selection bias. however, this is not 
surprising because of the inclusion criteria being 3 consecutive rises of Psa after 
reaching Psa nadir. only three patients were examined without the use of an 
erc. Due to the small number of this group no further conclusions can be drawn 
from this result. Because our current study is prospective and no other studies exist 
on defining true pharmacokinetic cut-off values for the irradiated prostate we 
had to base our cut-off values on the first two patients we imaged and biopsied. 
Defining a cut-off for tumour is impossible with only two patients. These two 
were only used to define a cut-off for “normal”. Above this “normal” threshold, 
radiologists then defined suspicious regions as focally enhancing spots shown on 
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the colour maps. To define true pharmacokinetic cut-off values for tumour vs. 
benign enhancing spots vs. normal in the irradiated prostate is subjective of a 
future publication and can only be determined retrospectively on a larger group 
of patients.
 salvage therapies can offer a possibility of cure in selected patients. this 
underlines the importance to select the patients who would benefit from it 
carefully (27). unfortunately, the conventional methods for diagnostic workup 
of Pca recurrence (e.g. Dre, Psa, trus, bone scan) all have their limitations. 
therefore, there is a need for more accurate and versatile diagnostic tools like 
Mr imaging, which has the advantage that both local and distant prostatic 
disease can be evaluated at the same time. Moreover, the addition of other 
functional Mr imaging techniques such as DWi can even possibly play a role in 
the assessment of tumour aggressiveness (28).
 in conclusion, the combination of MrgB and diagnostic Mr imaging of the 
prostate was a feasible technique to localize Pca recurrence after eBrt using a 
low number of cores in a clinically acceptable time.
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abstract 
purpose
to describe the technique of magnetic resonance (Mr)-guided biopsy as 
performed in our institution and highlight trends from current literature.
Materials and Methods
local protocols for Mr prostate cancer localization and its image data analysis is 
described. acquisition of a 3D localization for a tumour suspected region (tsr) and 
its re-identification on a second MR-guided biopsy session are being explained. 
furthermore, detailed information about the procedure, biopsy technique itself 
and current trends are being discussed and highlighted.
results
Mr-guided biopsies (MrgBs) have a higher tumour detection rate of prostate 
cancer in patients with clinical suspicion of prostate cancer and repeated 
negative transrectal ultrasound guided biopsies (trus-gB). it is a feasible and an 
accurate technique.
conclusion
Performance of Mr guided prostate biopsies, using suggested techniques, 
protocols and equipment is a feasible and accurate technique. it has proven to 
be an accurate method for detection of significant prostate cancer in men with 
repetitive previous negative biopsies.
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introduction
Prostate cancer was the most frequently diagnosed cancer in men in the united 
states in 2008, accounting for 25% of all cancers (1). early detection is very 
important because localized disease can be treated effectively (2). Digital rectal 
examination (DRE) and measuring the prostate specific antigen (PSA) level are 
the mostly widely used tests for the diagnosis of prostate cancer (Pca). however, 
the gold standard remains histopathological evaluation of tissue obtained during 
prostate biopsy.
 systematic transrectal ultrasound guided biopsy (trus-gB) is the most 
frequently used technique for detecting Pca in men, clinically suspect for 
malignancy. however, limitations of trus-guided biopsy, such as high false-
negative biopsy rate(3) or over- or underestimating of true gleason score (4), 
have led to a search for other localization and biopsy techniques. furthermore 
gray scale transrectal ultrasound inherently has a low sensitivity for localizing Pca 
(5). urologists are constantly faced with the dilemma of how to best manage 
a patient with an elevated Psa in which repeat trus-gB reveal no cancer, as 
these patients could still be harbouring clinically significant tumours. Among 
others, repeat biopsies and radical techniques like saturation biopsies have been 
performed to overcome these limitations. Detection rates of between 9-34% for 
repeat trus-gB and saturation biopsy have been described (6, 7).
 as a consequence of the poor performance, other techniques with higher 
sensitivities for localizing Pca are needed. Mri with its proven high sensitivity 
for tumour localization appears to fulfil this need and has been used to direct 
biopsies under direct Mr guidance( 8, 9).
 the current literature on MrgB of the prostate however, is limited and the 
few studies available have included small number of patients, excessively long 
imaging and biopsy times, and only used conventional t2-weighted (t2-w) Mr 
imaging to localize tsrs (10-12). Multi-modality Mri has proven to increase the 
localization accuracy of Pca (13, 14). in our institution we use the multi-modality 
approach to maximize detection capabilities.
 the objective of this article is to describe the technique of Mr-guided biopsy 
as performed in our institution and highlight trends from current literature.
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Materials and Methods
Localization MRI
Before biopsy, an Mr localization protocol is performed to identify possible Pca 
locations. a 3t Mr scanner (siemens trio tim, erlangen, germany) was used 
together with an endorectal coil (Medrad, Pittsburgh, u.s.a) and pelvic phased 
array coil. The endorectal coil is inserted and filled with a 40 ml perfluorocarbon 
preparation (foMBlin, solvay-solexis, Milan, italy). a localization Mri can also 
be performed without an endorectal coil, using the pelvic phased array coil for 
signal reception only, especially when there are contra-indications to endorectal 
coil insertion (such as anorectal surgery, inflammatory bowel disease). However, 
despite a reduced signal-to-noise-ratio, at 3t imaging with the pelvic phased 
array coils is of proven feasibility. Peristalsis is suppressed with an intravenous 
administration of 20 mg of butylscopolaminebromide (BuscoPan, Boehringer-
ingelheim, ingelheim, germany), an intramuscular administration of 20 mg 
butylscopolaminebromide and 1 mg of glucagon (glucagen, nordisk, 
gentofte, Denmark) intramuscular. 
 the imaging protocol was as follows: after fast evaluation of correct endorectal 
coil position with fast gradient echo imaging, t2-w turbo spin echo sequences 
are performed (TR 4260 ms/ TE 99 ms; flip angle 120; 3 mm slice thickness; echo 
train length 15; 180 x 90 mm field of view and 448 x 448 matrix) in axial, coronal 
and sagittal planes, covering the prostate and seminal vesicles. subsequently, 
diffusion weighted imaging (DWi) is acquired with a single-shot echo-planar 
imaging sequence with diffusion modules and fat suppression pulses. Water 
diffusion in 3 directions is measured using b-values of 0, 50, 500 and 800 s/mm2 
(TR of 2400 ms/ TE of 81 ms; 3 mm slice thickness; 204 x 204 field of view and 136 
x 136 mm matrix). Apparent Diffusion Coefficient (ADC)-maps are automatically 
calculated by the scanner software. finally, in order to perform dynamic contrast-
enhanced Mri ( Dce-Mri), transverse 3D t1-weighted gradient echo sequence 
(TR 800 ms/ TE 1.47 ms; flip angle 14; 3 mm slice thickness; field of view 230 x 230 
and 128 x 128 matrix) are used to obtain proton-density images, with the same 
positioning angle and centre as the transverse t2-weighted sequence (to allow 
calculation of the relative gadolinium chelate concentration curves), followed 
by 3D T1-weighted spoiled gradient-echo images (TR 38 ms/ TE 1.35 ms, flip angle 
14, 10 transverse partitions on a 3D slab, 3 mm section thickness, 230 x 230 mm 
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field of view, 128 x 128 matrix, GRAPPA parallel imaging factor 2) acquired during 
an intravenous bolus injection of a paramagnetic gadolinium chelate—0.1 mmol 
of gadopentetate dimeglumine (DotareM, guerbet, Paris, france) per kilogram 
of body weight, administered with a power injector (Spectris; Medrad) at 2.5 ml/
sec and followed by a 20-ml saline flush. With these two sequences, a 3D volume 
with 10 partitions is acquired every 2.5 seconds. 
Localization MR data analysis
for image evaluation, the acquired images are viewed on an analytical software 
workstation. the calculated pharmacokinetic Dce-Mri parameters and the 
calculated aDc-maps from DWi are projected as colour overlay maps over the 
t2-w images (15). a manual co-registration tool built into the software is used if 
patient related movement causes misregistration of the different Mri modalities. 
the criterion for tumour suspicious regions (tsr) on t2-w images is a relative low 
signal intensity region within the prostate. on Dce-Mri features of tumour (high 
Ve, Ktrans, Kep and negative WashOut) as defined by Engelbrecht et al. (16) 
and Fütterer et al. (14) are being used to detect TSRs as well as areas of restriction 
on aDc maps (17). eventually, information from t2w-imaging, Dce-Mri and 
DWi are combined and used to determine the three most suspicious tsrs. the 
prostate is divided into 22 different axial and sagittal regions, in order to make 
a 3D spatial position estimation of the identified TSR. Sagittally, the prostate is 
divided into 5 different slabs respectively: apex, apex-mid, mid, mid-basis, basis. 
axially, the apical and basal slabs are divided into simple quadrants, while the 
remaining three are divided into left and right peripheral zone with subdivisions 
of anterior horn, dorsolateral region and paramedian region. the transition 
zone is furthermore subdivided into quadrants (figure 1). also the left and right 
seminal vesicles are considered as two separate regions. thus, for each tsr, the 
exact location sagittally and axially is noted. During a second session this spatial 
information is used to translate and relocate the tsr on the t2-w images and 
direct the Mr-guided biopsy.
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figure 1: endorectal 3t Mri anatomical t2-weighted images with the prostate divided into different 
regions in order to make an 3D estimation of the location of the tumour suspicious region. (a) the different 
slabs sagittaly, base (B), mid-base (MB), mid (M), apex-mid (aM) and apex (a). axially, the apical (b) 
and basal (d) slabs are divided into simple quadrants, while the remaining three (mid-prostate) (c) are 
divided into left and right peripheral zone and left and right transition zone.
MR-guided biopsy
finally, after the initial tumour localization Mri (preferably within 2 weeks), 
patients receive a 3t Mr-guided biopsy (trio tim, siemens, germany) using 
a pelvic phased array coil and dedicated fDa approved Mr biopsy device 
(Invivo, Schwerin, Germany). All patients receive oral ciprofloxacin 500 mg 
(ciProXin, Bayer, leverkusen, germany) the evening before, on the morning of 
the biopsy, as well as 6 hours post biopsy as antibiotics prophylaxis. the prostate 
biopsies are performed with the patient in the prone position. Pelvic phased array 
coils are placed on the patient’s back as well as beneath the hips and pelvis. 
chloorhexidine/lidocaïne gel (instillagel, farco-PharMa gmbh, köln, germany) 
is used to facilitate insertion of the needle guider (filled with gadolinium) rectally. 
the needle guider is then attached to the arm of the Mr biopsy device. figure 2 
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shows the Mr-guided biopsy device with the patient in the prone position, lying 
on the scanner table with the needle guider inserted rectally. the needle guider 
can be adjusted to be rotated, moved forward and backward, and changed 
in height. 
 Relocation of the TSR, determined during the first MRI localization, is done 
by obtaining t2-w turbo spin-echo images in the axial direction (tr 3500 ms/
TE 116 ms, flip angle 180, slice thickness 3 mm, in-plane resolution 0.7 x 0.7 mm, 
number of slices 15) for anatomical visualization of the prostate and it is optional 
to obtain a DWi (see for details localization Mri) if the tsr is more evident on 
the DWI than on the T2-w images during the first localization MRI. The axial T2-w 
slices have a similar angulation relative to the dorsal surface of the prostate as 
during the localization Mr session. By using the 3D spatial position noted during 
the first localization MRI (sagitally the slabs and axially left/right peripheral zone/
transition zone) the desired TSR is re-identified. After relocation of the desired TSR, 
adjustments are made to the biopsy device to aim the gadolinium-filled needle 
guider exactly towards this region. in order to prevent prostate movement during 
examination, it is important to prevent pressure from the needle guider on the 
rectum wall before starting t2-w image acquisition. to make sure that this is not 
the case, it is possible to obtain fast t2-w true-fisP images primarily. in-between 
adjustments, fast T2-w TRUE-FISP images (TR 4.48ms/ TE 2.24; flip angle 70; 228 x 
228 mm field of view, 228 x 228 matrix, slice thickness 3mm) are made in the axial 
and sagittal direction (with an imaging time of 11 seconds for each direction) to 
visualize correct guider position and to plan further adjustments. after this position 
is fixed, tissue samples with an 18-gauge, fully automatic, core-needle, double-
shot biopsy gun (invivo, schwerin, germany) with needle length of 175 mm and 
tissue core sampling length of 20 mm, are taken. 
 after acquiring a biopsy, fast t2-w axial and sagital true-fisP images are again 
obtained with the needle left in situ to verify correct needle position relative to 
the desired tsr. this is done for each tsr. the number of biopsy cores taken is 
dependent on the certainty of correct needle position within the tsr and the size 
of the tsr. up to three different tsrs are biopsied.
90 figure 2: Patient lying in prone position with biopsy device and needle guide inserted rectally.
Histopathology 
Samples are subsequently processed by a routine fixation in formaldehyde, 
embedded in paraffin, stained with hematoxylin-eosin, before being evaluated 
by a histopathologist for the presence of tumour or other benign pathologies.
results
results from the few studies that have already been performed on this technique 
have proven the feasibility, but imaging and biopsy times vary substantially (10-
12). Median imaging times of 30 minutes and a median number of 4 biopsies per 
patient can be achieved with the above described method. additionally, as 
mentioned before, the method for localization of tumour suspicious regions prior 
to biopsy vary with most researchers using t2-w imaging only. We believe that a 
multi-modality approach will result in the highest tumour detection rate.
 the described method of translation of Mri determined tsrs to t2 weighted 
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images in order to perform Mr guided biopsy is a feasible technique (figure 3)
(18). in our initial experience we have shown a tumour detection rate of 38% 
but this increased to 59% after gaining more experience (hambrock et al. the 
value of 3 tesla Magnetic resonance imaging guided Prostate Biopsies in Men 
with repetitive negative Biopsies and elevated Psa. submitted). furthermore our 
latest results indicate that for patients with Psa < 20 and prostate volumes < 65 
cc, MRGB significantly outperforms repeat TRUS-GB session in tumour detection. 
of note is also that Mri for tumour localization and MrgB does not appear 
to overdiagnose indolent cancers, a fear that is justified as a higher tumour 
localization implies a higher chance of detecting clinically insignificant tumours. 
Of all our tumours detected 93% were of clinical significance (Hambrock et al. 
the value of 3 tesla Magnetic resonance imaging guided Prostate Biopsies in 
Men with repetitive negative Biopsies and elevated Psa. submitted). using a 
higher field strength of 3T for both tumour localization and biopsy, offers improved 
image quality and acquired in a shorter time frame, 1.5t will however also be 
suitable for both localization and detection.
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figure 3: shows pelvic phased array coil 3t Mr images of a 70 year old male (Psa 35 ng/ml) in which 
six previous trus-guided biopsies failed to detect the transition zone tumour. this area showed low 
signal intensity on t2-weighted axial images (a), restriction on the aDc map (b) and a high ktrans on 
Dce-Mri (c). an Mr guided biopsy of this region was obtained (d) and histopathology revealed an 
adenocarcinoma with a gleason score of 6.
discussion 
Using state-of-the-art multi-modality MRI for tumour localization a definite 
diagnosis of prostate cancer can be made in a substantial number patients 
with clinical suspicion of prostate cancer based on elevated Psa values and 
repeated negative trus-gB. MrgB has been shown to be of added value in 
this particular group of patients (10-12,19) and can help urologists to improve 
their biopsy outcome. in addition, biopsy under direct Mr guidance, is not only 
feasible, but also leads to a high number of patients being identified with clinically 
significant tumour. MRGBs are limited by the restricted general availability of 
the required hardware and therefore other methods such as trus-Mri fusion 
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(20) could be considered. nevertheless, MrgB is probably the most accurate 
technique because translation of a tumour suspicious region (tsr) to another 
imaging modality is not required. 
 Performance of Mr guided prostate biopsies, using suggested techniques, 
protocols and equipment is a feasible and an accurate technique. Mri is 
deemed essential in the work-up of all patients with suspicion of cancer but 
repeat negative trus-gBs. MrgB can offer a value method to accurately 
validate findings of multi-modality MRI in these patients. It can be a valuable 
addition in the arsenal of clinicians in managing these problematic patients with 
repetitive previous negative biopsies (19).
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abstract
In men with an elevated prostate-specific antigen and/or abnormal digital rectal 
examination biopsy is the gold standard for prostate cancer (Pca) diagnosis. 
random systematic transrectal ultrasound guided prostate biopsy (trusgB) is the 
most widely applied and available Pca diagnosis method. Detection rates of 
PCa in random systematic TRUSGB do not exceed 44% and 22% for the first and 
second biopsy session, respectively (2,3). consequently other biopsy methods 
have been explored. one of these methods is Mr guided biopsy (MrgB) of the 
prostate which has detection rates after previous negative trusgB sessions of 
between 38-59% (18-23). these rates are higher compared to repeat trusgB.
MRGB typically consists of two sessions. In the first session a diagnostic multi-
parametric Mr of the prostate is acquired and subsequently cancer suspicious 
regions (csr) are determined. in the second session these csr will be targeted 
for MrgB. the use of multi-parametric Mr imaging in Pca diagnosis could 
prevent patients from undergoing unnecessary biopsies and consequently avoid 
unnecessary treatment delay. 
 in conclusion, MrgB has a high Pca detection rate in patients with previous 
negative trusgB sessions. for this reason MrgB will probably become more and 
more available in daily practice. however, the lack of standard protocols for Mr 
imaging of the prostate is an important issue. for the optimal biopsy technique 
there is still more research necessary. robotics may optimize MrgB regarding 
target accuracies and procedure time. 
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introduction
In men with an elevated prostate-specific antigen and/or abnormal digital rectal 
examination biopsy is the gold standard for prostate cancer (Pca) diagnosis. 
random systematic transrectal ultrasound guided prostate biopsy (trusgB) is 
the most widely applied and available Pca diagnosis method. according to 
the guidelines of the european association of urology on Pca, depending on 
prostate volume, a minimum of 8 cores should be sampled with a maximum of 12 
cores (1). Detection rates of Pca in random systematic trusgB do not exceed 
44% and 22% for the first and second biopsy session, respectively (2,3). This ‘blind’ 
prostate sampling often results in under sampling of the anterior prostate and 
apex. As a result of this ‘blind’ biopsy strategy (36% negative predictive value (4)), 
many men are falsely reassured that they are free of cancer when they are not. 
consequently other biopsy methods have been explored. saturation biopsies, 
either transperineal or transrectal, have been proposed in patients with multiple 
prior negative trusgB sessions. the term saturation biopsy is used to describe 
biopsy schemes with a minimum of 20 cores. even with such drastic biopsy 
schemes, detection rates of only maximally 34% have been reported in patients 
with negative previous biopsy sessions (5). Moreover, such biopsy schemes can 
be associated with increased patient morbidity, such as urinary retention and 
hematuria requiring treatment (6). furthermore there is an ongoing debate on 
whether the risk of detecting more insignificant tumours is higher in saturation 
biopsy (7). in all probability, it is not the number of biopsy cores which makes 
trusgB imprecise, rather the random way of sampling the prostate without 
any sensitive imaging technique. there is a real need for an adequate imaging 
technique, which ideally localizes, determines Pca aggressiveness and estimates 
tumour volume in a non-invasive fashion. subsequently, this information can serve 
for targeting biopsies and e.g. for focal therapy. 
 Mr imaging of the prostate, with its multi-parametric approach, is the best 
available technique for Pca detection and localization (8-10). areas under 
the curve of 0.90 have been described when t2-weighted imaging (t2-w), 
dynamic contrast-enhanced (Dce-Mri) and spectroscopic imaging (Mrsi) were 
combined (10). Moreover, adding diffusion weighted imaging (DWi) revealed a 
significant negative correlation between Gleason grade and apparent diffusion 
coefficient (ADC) values (11-13), implicating that it can serve as targeting the 
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most aggressive part of the Pca during biopsy. although the number of studies 
are scarce, there is accumulating evidence that multi-parametric Mr imaging is 
also sensitive to measuring tumour volume (14-16).
 in 2010 hambrock et al. (17) published a study on detection rates in 
transrectal Mr guided prostate biopsy (MrgB) in men with at least 2 negative 
prior trusgB sessions. targeted biopsies were performed based on preceded 
3 tesla diagnostic multi-parametric Mr examination. With a median of 4 cores 
per patient they reported a detection rate of 59%. in 68% of the cases Pca was 
detected in the anterior aspect of the prostate, which is not sampled standardly 
in random trusgB. ninety three percent of the detected cancers on MrgB were 
clinically significant. Also other authors have provided data of MRGB in patients 
with previous negative trusgB (18-23) (table 1). MrgB can also be applied 
to detect local recurrences after radiotherapy (24). MrgB of the prostate is 
becoming more and more available. however there is no consensus on the 
optimal technique. recent studies describing the role of robotics in prostate 
biopsy have been published (25-27). 
 this chapter will give an overview on the pre-biopsy planning session of 
detecting cancer suspicious regions (csr) in the prostate, how to perform MrgB, 
and the role of robotics in MrgB.
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table 1
overview on Mrgb literature
authors patient group field strength diagnostic 
imaging protocol
detection rate
Beyersdorff et al. 
radiology 2005
Patients with previous 
trusgB
1.5t t2-w 45%
engelhard et al. eur 
radiol 2006
Patients with previous 
trusgB
1.5t t2-w 39%z
anastasiadis et al. eur 
urol 2006
Patients with previous 
trusgB
1.5t t2-w 55%
hambrock et al. ir 
2008
Patients with previous 
trusgB
3t t2-w, DWi, Dce-
Mri
38%
Hambrock et al. J 
urol 2010
Patients with previous 
trusgB
3t t2-w, DWi, Dce-
Mri
59%
yakar et al. ir 2010 Patients with suspicion 
of post-radiotherapy 
recurrence
3t t2-w, Dce-Mri 75%
Roethke et al. World J 
urol 2011
Patients with previous 
trusgB
1.5t Partly t2-w, partly 
t2-w, DWi, Dce-
Mri, Mrsi
52%
franiel et al. 
radiology 2011
Patients with previous 
trusgB
1.5t t2-w, DWi, Dce-
Mri, Mrsi
39%
MrgB= Mr guided prostate biopsy, trusgB= transrectal ultrasound guided prostate biopsy, t2-w= t2 
weighted, DWi= diffusion weighted imaging, Dce-Mri= dynamic contrast-enhanced Mri, Mrsi= Mr 
spectroscopic imaging
pre biopsy planning session
MRGB typically consists of two sessions. In the first session a diagnostic multi-
parametric Mr of the prostate is acquired. although there is an ongoing discussion 
on the optimal imaging protocol, such a protocol should include at least t2-w, 
DWi, Dce-Mri and/or Mrsi (21). additionally, csr detected on these Mr images 
need to be reported structurally. a structured report is of paramount importance 
to enable a successful transfer of these csr to the MrgB session. During a MrgB 
session the two most suspicious csr should be biopsied (as a minimum). figure 1 
shows an example of a first diagnostic multi-parametric MR imaging session with 
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an example of a structured report. Most practical is to score for every csr for 
each different Mr parameter the likelihood of cancer being present. a scale of 
1-5 can be used, where a score of 1 indicates no cancer present and a score 
of 5 indicates that cancer is highly likely to be present. although it is beyond the 
scope of this chapter (see chapter on prostate Mri for more detailed information), 
criteria per parameter for scoring cancer presence in short are; a focal area of 
low signal intensity on t2-w, on the Dce-Mr images a focally enhancing region 
on the volume transfer constant map and/or washout map, and on the DWi a 
focally low-signal intensity region on the apparent diffusion coefficient map in 
combination with a high-signal-intensity region on the image obtained with a 
high b value (e.g. 800 sec/mm 2). 
a b c
Summary of findings (NA = Not available, 1 = def. no tumour, 5 = def. tumour)
t2 DWi Dce total extracapsular
extension
finding marking 1 5/5 5/5 5/5 15/15
d
e
figure1: Multi-parametric Mr images, comprising t2-weighted (a), diffusion weighted-derived apparent 
diffusion coefficient map images (b), and dynamic-contrast enhanced images (k-trans) (c), in a 75 
year old patient, with a Psa of 15 ng/ml, and a history of 2 negative transrectal ultrasound guided 
prostate biopsy sessions. The white circle depicts the areas suspicious for malignancy. These findings 
were summarized in a structured report. firstly the cancer suspicious area was scored for the likelihood 
of cancer being present on 1-5 scale (d). secondly, a 3 dimensional position estimation was determined 
(e) for targeting purposes during the Mr-guided biopsy session.
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patient preparation
it is advisable to prepare patients preventively with oral or intravenous 
quinolones. Patients with indications for endocarditis prophylaxis and patients 
on anti-coagulation medication should be recognized, and if necessary further 
adjustments should be made depending on hospital protocols. no further 
preparation is necessary, such as special diets or enema’s. Patients should be 
instructed not to move during the intervention. The first MRGB were performed 
in open-bore Mr systems. open-bore Mr systems suffer from low signal to noise 
ratios (due to low field strength) and consequently from low image quality. 
Therefore, ideally MRGB should be performed in a closed bore system (≥ 1.5 
tesla). at the same time the hindrance of a closed bore system is the limited 
space one has to position the patient, perform specific manoeuvres and handle 
instruments required for certain interventions. such problems may be overcome 
till a certain level with newer Mr systems with larger and shorter bores. Moreover 
robotics can also assist in overcoming these above-mentioned problems.
 as for biopsy routes, the transrectal approach is probably the most preferable 
one. even though transgluteal and transperineal biopsy methods have been 
described and seem feasible, the transrectal approach is the only method where 
anaesthetics can be omitted (28,29). 
 in a placebo-controlled, double-blind study, the authors concluded that pain 
involved in trus biopsy of the prostate is well tolerated, without the need for 
anaesthesia (29). in addition, the rectum is the shortest way to reach the prostate 
and therefore technically the most straightforward approach. it will suffer the 
least from e.g. needle deflection. Concerning complication rates transrectal and 
transperineal biopsy are equally safe (28,30). there are no studies comparing 
morbidity rates between the three biopsy routes.
how to perforM Mr guided prostate biopsies
Beyersdorff et al. (18) were the first to describe a transrectal MRGB in a closed 
Mr system by using only t2-w Mr images as part of a pre-biopsy planning. More 
recently, hambrock et al. (17) and franiel et al. (23) described transrectal MrgB in 
a closed Mr system by using a multi-parametric Mr pre-biopsy planning method. 
there are currently two commercially available devices for MrgB (figure 2 and 
3). the latter device has 5 degrees of freedom (rotation, forward and backward, 
change in height). Patients are placed in a prone or supine position on the Mr table 
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where a needle guider filled with gadolinium is inserted rectally, after lubricating 
it with lidocaine gel. a body phased-array coil is placed on the patient (figure 4). 
once the patient is in the Mr scanner the csr determined during the diagnostic 
Mr session need to be relocated. for this, these csr need to be translated to the 
t2-w images obtained during the biopsy session by using anatomical landmarks 
and a relative 3 dimensional position estimation (figure 1e) (21). in certain cases 
it is advisable to obtain a DWi sequence just before the biopsy. in this way the 
most aggressive part of the csr can be targeted (11-13). after relocation of the 
csr the needle guider is adjusted towards the desired target area, a fast t2-w 
true fast imaging with steady state precession verification image in at least two 
planes (preferably in the axial and the sagittal plane) is acquired to determine 
the needle guider’s position relative to the targeted area. Both commercially 
available systems have software systems for correct alignment of needle guider 
with target area. When satisfied with its location a biopsy can be performed and 
a verification image with the needle left in situ can be obtained (Figure 5). An 
18-gauge, fully automatic, Mr-compatible, core needle, double-shot biopsy gun 
with a needle length of 150/175 mm and tissue core sampling length of 17 mm 
can be used for this. Depending on how confident one is about the accuracy 
of the biopsy relative to the csr, additional biopsies can be taken. a procedure 
time of 35 minutes (17,22) is reachable, after a learning curve of probably 30-40 
cases. 
 the expected morbidity after MrgB are more or less comparable to random 
trusgB, which are hematospermia (for about 4 weeks after the procedure), 
hematuria (for about a week after the procedure), and anal bleeding (one or 
two days after the procedure). sporadically sepsis can develop (<1%). even 
though it is conceivable that MrgB will have less complications due to the lower 
number of cores taken per patient, no studies report on the comparison of MrgB 
and trusgB complications.
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figure 2: Biopsy device for patient positioning (invivo, schwerin, germany).
figure 3: Biopsy device for patient positioning (hologic, toronto, canada). Photo courtesy of hologic, 
inc. © 2011. all rights reserved.
106 figure 4: Patient lying in prone position with biopsy device and needle guider inserted rectally.
a b
figure 5: During a second session, a Mr-guided biopsy was performed of the cancer suspicious area 
depicted at figure 1. The needle guider was pointed towards the cancer suspicious region in axial (a) 
and sagittal plane (b) and subsequently biopsied. Verification images with the needle guider left in situ 
was obtained. histopathology revealed a gleason 4+4 prostate cancer.
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robotics
MrgB as described above is a manual procedure where the needle guider 
movements have to be adjusted by hand. since access within the closed bore 
Mr scanner is limited for manual manipulation of instruments, every adjustment 
requires the patient to be moved in and out of the scanner. as a consequence a 
great amount of time is spent on instrument adjustment. robotics or manipulators 
can be very practical in such situations. however, designing a Mr-compatible 
robot which can be used in the restricted space and environment of the Mr scanner 
is a very challenging task. several demanding issues have to be considered, such 
as selecting Mr-compatible materials, constructing Mr-compatible actuators 
and position sensors, and designing a robot to image registration system that 
allows guidance of the robot based on Mr image feedback (31).
 at the moment there are only 3 sites where Mr-compatible robotics in closed 
bore systems for prostatic interventions have been investigated. Most of these 
studies have focused on transperineal needle or brachytherapy seed placement 
(25-27). two studies reported on the feasibility of MrgB with the aid of robotics 
(32,33). one of these studies examined the transgluteal approach in biopsying 
suspicious prostate lesions (32). the other study used the transrectal approach 
(without the use of anaesthesia) where manipulation time of moving the needle 
guide from csr to csr had a median of 2.5 minutes (33). these preliminary results 
are promising and the use of robotics in MrgB may eventually lead to lesser 
biopsy procedure time and higher target accuracies. nevertheless, with only 4 
studies reporting on this subject, there is still more research necessary in order to 
proof the utility of robotics in MrgB.
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discussion 
the detection rates for MrgB after previous negative trusgB sessions range 
between 38-59% (18-23) (table 1). these rates are higher compared to repeat 
trusgB, which has a detection rate of maximally 22% in a second session (2,3). 
also noteworthy in table 1, is the general trend towards higher detection rates 
in multi-parametric Mr imaging preceded MrgB compared to only anatomical 
t2-w Mr imaging preceded MrgB.
 MrgB has the advantage of being a targeted procedure, directed by the 
preceding diagnostic Mr session with promising localization performance. also 
the excellent soft tissue contrast during the biopsy itself is a major advantage of 
this technique. the use of multi-parametric Mr imaging in Pca management 
could prevent patients from undergoing unnecessary biopsies and consequently 
avoid unnecessary treatment delay. the lack of standard protocols for Mr 
imaging of the prostate is an important issue, however it is still the best available 
imaging technique in Pca localization, determining aggressiveness and tumour 
volume. another advantage of multi-parametric Mri is the low sensitivity for low 
grade and/or low volume disease, therefore potentially only detecting clinically 
significant disease. As more studies concerning multi-parametric MR imaging 
in Pca will follow, it will only be a matter of time till standardized protocols will 
be developed. another major argument of opponents of Mr imaging in the 
management of Pca is the supposedly high costs involved. of interesting note, 
the costs involving saturation biopsy has been an estimated $5000 more than 
standard trus biopsy (6).
 trusgB is more available worldwide compared to MrgB. the information 
obtained from the diagnostic Mr session could be used to direct trusgB. this 
information can be visually transferred to the trus images. it is conceivable 
that this method will suffer a great deal from spatial misregistration. to reduce 
this misregistration fusion algorithms are currently developed. currently, Mr 
localization information can also be fused with the help of commercially 
available software packages with trus images (34), which is a work in progress. 
concerning target accuracies it is imaginable that MrgB will suffer the least 
from spatial misregistration because the same two techniques are being used 
for localization and biopsy. however, there are no studies comparing target 
accuracies between trus-Mr imaging fusion and MrgB.
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furthermore, robotics will most likely play a larger future role in MrgB and 
interventions. However, there is still more research necessary in order to define 
the optimal technique. future studies should concentrate on determining what 
the most accurate, fastest, and cost-effective technique is. 
 in conclusion, MrgB has a high Pca detection rate in patients with previous 
negative trusgB sessions. for this reason MrgB and/or trus-Mr fusion guided 
biopsy will probably become more and more available in daily practice. for the 
optimal biopsy technique there is still more research necessary. robotics may 
optimize MrgB regarding target accuracies and procedure time.
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abstract 
purpose
to assess the feasibility of using a remote-controlled, pneumatically actuated 
magnetic resonance (Mr)-compatible robotic device to aid transrectal biopsy 
of the prostate performed with real-time 3-t Mr imaging guidance.
Materials and Methods
this prospective study was approved by the ethics review board, and written 
informed consent was obtained from all patients. twelve consecutive men 
who were clinically suspected of having prostate cancer and had a history of 
at least one transrectal ultrasonography guided prostate biopsy with negative 
results underwent diagnostic multi-parametric Mr imaging of the prostate. two 
radiologists in consensus identified cancer-suspicious regions (CSRs) in 10 patients. 
these regions were subsequently targeted with the robot for Mr imaging–guided 
prostate biopsy. to direct the needle guide toward the csrs, the Mr-compatible 
robotic device was remote controlled at the Mr console by means of a controller 
and a graphical user interface for real-time Mr imaging guidance of the needle 
guide. the ability to reach the csrs with the robot for biopsy was analyzed.
results
a total of 17 csrs were detected in 10 patients at the diagnostic Mr examinations. 
these regions were targeted for Mr imaging–guided robot-assisted prostate 
biopsy. thirteen (76%) of the 17 csrs could be reached with the robot for biopsy. 
Biopsy of the remaining four csrs was performed without use of the robot. 
conclusion
it is feasible to perform transrectal prostate biopsy with real-time 3-t Mr imaging 
guidance with the aid of a remote-controlled, pneumatically actuated Mr-
compatible robotic device.
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introduction
in patients clinically suspected of having prostate cancer—that is, those with 
suspicious digital rectal examination findings and/or an elevated prostate 
specific antigen level—transrectal ultrasonography (US)–guided prostate biopsy 
is recommended (1). transverse us–guided biopsy, despite the systematic course 
of sampling involved, reportedly has relatively low sensitivity (33%–44%) and a 
considerably high false negative result rate (23%) (2–4). thus, persistent suspicion 
of prostate cancer after repeated transverse us–guided biopsies with negative 
results is common (5,6) and can create emotionally stressful situations. Physicians 
and patients are faced with the dilemma of determining whether they are 
dealing with missed cancer or benign disease. 
 for these reasons, lesion-directed magnetic resonance (Mr) imaging–guided 
biopsy of the prostate has been proposed. some promising results, including high 
tumour detection rates and a minimal number of biopsy core specimens per 
patient, have been published (7–9). a major advantage of Mr imaging–guided 
biopsy is the use of diagnostic Mr imaging, which not only yields excellent 
soft-tissue contrast to localize cancer-suspicious regions (csrs) but also can 
help guide the intervention. Mr imaging is considered a reliable technique for 
localizing prostate cancer and is now being performed in many institutions. 
Performing multi-parametric Mr imaging, the preferred approach, involves 
obtaining t2-weighted, diffusion-weighted, Mr spectroscopic, and dynamic 
contrast material–enhanced images (10–16). 
 the use of robotics during an Mr imaging–guided intervention can be very 
helpful. robot use has been investigated for neurosurgical applications (17,18) 
and prostatic interventions such as needle and seed placement in brachytherapy 
(19–21). for Mr imaging–guided prostate biopsy procedures, which are typically 
performed with a manually adjustable device (22), robotics can be valuable for 
aligning the needle guide with the target area. the majority of the procedure 
time in Mr imaging–guided prostate biopsy is spent repeatedly moving the 
patient in and out of the Mr unit for device manipulation to facilitate correct 
alignment of the needle guide with the csr. 
 in contrast to the investigators in the aforementioned studies of robot-
assisted transperineal prostatic interventions (19–21), we used the transrectal 
approach for prostate biopsy in the current study. for biopsy in particular, this 
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approach might be more advantageous because of the possibility to perform 
biopsy without the need for anaesthetics. in a recently published randomized 
placebo-controlled, double- blind study, the investigators concluded that the 
pain involved in transrectal us–guided biopsy of the prostate is well tolerated, 
without the need for anaesthesia (23). furthermore, when the transrectal and 
transperineal approaches were compared (in 246 patients) in a randomized 
controlled trial, no significant differences in complication rates were found (24). 
the purpose of this study was to assess the feasibility of using a remote-controlled, 
pneumatically actuated Mr-compatible robotic device as an aid in performing 
transrectal biopsy of the prostate with real-time 3-t Mr imaging guidance. 
Materials and Methods
Patients 
this prospective study was approved by the ethics review board of our 
institution, and written informed consent was obtained from all patients. from 
September 2009 to March 2010, 12 patients with a prostate-specific antigen 
level of 4 ng/ml or higher and a history of at least one transverse us–guided 
prostate biopsy procedure with negative results were referred for diagnostic 
multi-parametric Mr examination of the prostate. ten of these patients, who 
had csrs, were prospectively enrolled in our study. in a second Mr examination, 
the csrs were targeted with an in-house–developed Mr-compatible robot 
(Bosboom engineering, vriezenveen, the netherlands) that was used as an aid 
in performing Mr imaging– guided prostate biopsy. the exclusion criteria were 
contraindications to Mr imaging (e.g., cardiac pacemakers, intracranial clips). 
Diagnostic MR Imaging
Mr imaging of the prostate was performed by using a 3-t Mr system (siemens 
Trio Tim; Siemens Healthcare, Erlangen, Germany) and a pelvic phased-array 
coil. Peristalsis was suppressed by means of intravenous injection of 20 mg of 
butylscopolamine bromide (Buscopan; Boehringer-Ingelheim, Ingelheim, 
Germany) and 1 mg of glucagon (Glucagen; Nordisk, Gentofte, Denmark). 
the diagnostic Mr examination took 17 minutes and included the following 
sequences: t2-weighted turbo spin-echo imaging was performed by using 3070– 
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4010/104–107 (repetition time msec/echo time msec), a flip angle of 120°, a 
section thickness of 3–4 mm, an echo train length of 15, a field of view of (180–256) 
x (180–222) mm, and a matrix of (320–448) x (320–448) in the sagittal, coronal, and 
axial planes. axial diffusion-weighted imaging was performed by using 2300/61, a 
section thickness of 4 mm, a field of view of 256 x 216 mm, a matrix of 128 x 128, 
and b values of 50, 500, and 800 sec/mm 2 with construction of apparent diffusion 
coefficient maps. Before the administration of contrast material (gadoterate 
meglumine, Dotarem; Guerbet, Paris, France), a three-dimensional proton 
density– weighted sequence was performed by using 800/1.47, a flip angle of 8°, 
a section thickness of 4 mm, a field of view of 230 x 230, and a matrix of 128 x 128. 
after the intravenous bolus injection of 15 ml of gadoterate meglumine, dynamic 
contrast-enhanced Mr imaging was performed by using a three-dimensional t1-
weighted spoiled gradient-echo sequence with equal spatial resolution and the 
following parameters: 32/1.47, a flip angle of 10°, a section thickness of 4 mm, a 
field of view of 230 x 230 mm, and a matrix of 128 x 128, with 35 measurements 
performed in 2 minutes 43 seconds.
MR Data Analysis
Two radiologists (J.O.B., J.J.F., 16 and 6 years of experience, respectively, 
reading prostate MR images) in consensus identified the CSRs. All MR imaging 
results were interpreted at an analytical software workstation, where dynamic 
contrast-enhanced Mr imaging–derived pharmacokinetic parameters 
were calculated by using the standard two compartment model (25) and 
the reference tissue method for arterial input function estimation (26) and 
diffusion weighted imaging–derived apparent diffusion coefficient maps were 
calculated with the mono-exponential decay fit to the signal versus b value. 
Both the pharmacokinetic parameters and the apparent diffusion coefficient 
maps were projected as colour maps overlaid on the t2-weighted Mr images. 
A CSR was defined as such when abnormal findings were present on at least 
one of the following images: on t2-weighted images a relatively low signal-
intensity region, on the dynamic contrast-enhanced volume transfer constant 
map and/or washout map a focally enhancing region, and on the diffusion 
weighted imaging apparent diffusion coefficient map a focally low-signal 
intensity region in combination with a high-signal-intensity region on the image 
obtained with a b value of 800 sec/mm 2. for each csr, the location was 
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annotated by using three-dimensional spatial position estimation. for these 
annotations, the prostate was divided into 22 axial and sagittal segments on 
the t2-weighted images (22). this information was used to relocate the csrs 
during the biopsy procedure. 
MR-Compatible Robotic System
the robotic system was developed in house and de novo. the robot was 
designed to function with the patient in any standard closed-bore clinical Mr 
system. the entire device was constructed of Mr-compatible (i.e., nonmagnetic 
and nonconductive) materials to prevent Mr image artefacts due to distortion of 
the magnetic field and to ensure patient safety. The robotic system consisted of 
the robot itself (figure 1, d) and a controller unit (comprising a computer, motion 
control elements, and electropneumatic and electronic interfaces) located 
outside the Mr radiofrequency shield. compressed air for the pneumatic motors 
that was generated in a compressor outside the Mr imaging room was delivered 
to the robot through plastic tubes. therefore, no electricity was required inside 
the Mr imaging room. clicking on the corresponding arrow required to prompt a 
certain movement initiated motion of the needle guide: the corresponding valve 
was opened and generated a wave of pressure to the corresponding motor. on 
a separate screen, a graphical user interface ife enabled real-time Mr image 
monitoring of the intervention. 
 The robotic system enables positioning of the needle guide with five degrees 
of freedom, with translations in three directions (anterior-posterior, inferior-
superior, and lateral) and rotations in two directions (inferior-superior and lateral). 
The angle of the needle guide in relation to the main magnetic field could range 
from 30° to 55° in the inferior- superior direction and plus or minus 26° in the lateral 
direction (27). to ensure patient safety and meet standard safety requirements for 
use in a medical environment, the needle guide had a built-in mechanical safety 
mechanism consisting of a suction cup. only a maximal set amount of force was 
allowed to be exerted on the patient, after which the safety mechanism was 
released (27). 
Biopsy Procedure 
During the second part of the Mr examination, with the patient in the closed-
bore 3-t Mr system, the csrs were targeted with the robot by using a transrectal 
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approach. One radiologist (D.Y.) operated the robotic device; however, either 
two radiologists or a radiologist and a technician were required to position the 
patient and set up the system. All patients received 1000 mg of ciprofloxacin 
(Ciproxin; Bayer, Leverkusen, Germany) orally the evening before the biopsy, the 
morning of the biopsy, and 6 hours after the procedure. 
 Biopsy was performed with the patient in the prone position and the needle 
guide (invivo, schwerin, germany) inserted rectally. the needle guide was 
attached to the arm of the robotic device (figure 2). a pelvic phased-array coil 
was placed on the buttocks of the patient. to relocate the annotated csr, a 
sagittal T2-weighted half-Fourier single shot turbo spin-echo image (2180/116, 120° 
flip angle, 6-mm section thickness, echo train length of 15, 350 3 317-mm field of 
view, matrix of 256 x 205, imaging time of 31 seconds) and a coronal t2-weighted 
turbo spin-echo image (3540/102, 120° f lip angle, 4-mm section thickness, echo 
train length of 15, 256 x 252-mm field of view, matrix of 256 x 256, imaging time of 
3 minutes) were acquired. the coronal t2-weighted turbo spin-echo sequence 
was used to select the section that corresponded to the exact location of the 
csr, which was subsequently exported to the ife monitor. in addition, a real-time 
true fast imaging with steady-state precession sequence (894/2.3, 60° flip angle, 
5-mm section thickness, 300 x 300-mm field of view, 192 x 192 matrix, imaging time 
of 0.9 second per plane [total imaging time for all three planes, 2.7 seconds]) was 
performed repeatedly in the coronal, sagittal, and axial planes. these images 
were exported to the ife monitor in real time for visualization of the movement 
of the needle guide. the robot controller, located on a separate computer 
next to the ife monitor, was used to remotely change the position of the needle 
guide. after the needle guide was correctly aligned with the targeted csr, a 
T2-weighted true fast imaging with steady-state precession image (4.48/2.24, 70° 
flip angle, 3-mm section thickness, 228 x 228-mm field of view, 228 x 228 matrix, 
imaging time of 11 seconds) was acquired in the axial direction, from behind the 
Mr console, to measure the biopsy depth (figure 1). 
 finally , the actual biopsy procedure was performed manually. for this, the 
patient had to be removed from the bore, and an Mr-compatible, 18-gauge fully 
automatic core-needle double-shot biopsy gun (invivo) with a needle length of 175 
mm and a tissue core sampling length of 17 mm was used. after the biopsy, the 
patient had to be moved back into the bore, with the needle left in situ. another t2-
weighted true fast imaging with steady-state precession image was then obtained 
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to verify the position of the needle relative to the desired csr. all biopsies were 
performed by one radiologist (D.y.) with 1½ years of experience performing manual 
MR imaging– guided biopsy of the prostate. After verification of the needle position 
relative to the desired csr and with the needle still in situ, the number of biopsy 
samples per csr was determined on the basis of the certainty of the correct needle 
positioning. for each patient, the setup time (including robot setup and patient 
positioning), the time from movement of the needle guide from one csr to another 
csr, and the duration of the entire biopsy procedure were noted.
Histopathologic Analysis 
The biopsy samples were subsequently processed. They were routinely fixed in 
10% buffered formalin, embedded in paraffin, and stained with hematoxylineosin 
before being evaluated for the presence of prostate cancer or benign 
abnormalities. all biopsy samples that were positive for prostate cancer were 
assigned a gleason score.
d
c
a
b
figure 1: robotic system setup, including Mr console, interactive front end (ife) monitor, robot software 
controller, and robotic device itself. after patient positioning in Mr unit, imaging is started from the 
console (a) , and the image is sent to the ife monitor (b), where, on the basis of the real-time image 
fi ndings, the needle guide is adjusted and directed toward the CSR by using the controller (c). this 
eventually results in motion of the robot (d).
123
c
hapter 7
robot for M
rg
B
figure 2: rectal insertion of needle guide attached to robot, after patient is positioned prone in the Mr 
system.
results
Patient characteristics are listed in the Table. A total of 17 CSRs were identified 
(figures 3, 4) in 10 patients. a median of 1.5 csrs (range, 1–2) per patient were 
identified, a median of two biopsy samples per CSR were taken (range, 1–3), and 
a median of three biopsy samples (range 1–5) per patient were obtained. four 
csrs, two of which were in the same patient, were not reachable with the robot 
for biopsy: one patient who had two csrs, in the apex and in the base of the 
prostate, was not positioned correctly; he was positioned outside the pivoting 
point of the needle guide, and this resulted in a limited range of movements of 
the needle guide in the rectum. the remaining two csrs, in two patients, were 
located in the apex of the prostate gland. to reach these apical regions, the 
robot had to rotate the needle guide more caudally in the sagittal plane, and 
this could be achieved only by means of cranial movement of the angulation 
rail. however, cranial movement of the angulation rail was restricted by the size 
of the magnet bore (60 cm). 
 ultimately, four of the 17 csrs, in one of the 10 patients, were manually 
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sampled without use of the robot and thus were excluded from further analysis in 
this study. there were no complications related to the prostate biopsy procedure 
in terms of bleeding, infection, sepsis, or other medical conditions.
Procedure Time
the entire biopsy procedure was completed within a median time of 76.5 minutes 
(range, 45–105 minutes). this was exclusive of the median setup time (e.g., for 
robot setup, patient positioning), which took an average of 15 minutes (range, 
10–20 minutes) per patient. the median time for movement of the needle guide 
from csr to csr was 2.5 minutes (range, 1–5 minutes).
table 1
patient characteristics
characteristic Datum (range)
total number of patients 9
Median age (y) 69 (59-72)
Median number of negative trus guided biopsy 
procedures per patient
3 (1-4)
Median psa (ng/ml) 19.5 (10-26)
Median time between diagnostic Mri and robot Mr-
guided biopsy (days)
53 (14-119)
TRUS = transrectal ultrasound, PSA = prostate specific antigen
Histopathologic Findings
On a patient-by-patient level, five (56%) of nine patients received a diagnosis 
of prostate cancer. on a csr-by-csr level, six of 13 csrs contained prostate 
cancer (gleason scores: 3 + 3, 3 + 3, 3 + 4, 3 + 4, 3 + 5, and 4 + 4), and all of them 
were located in the ventral aspect of the prostate. three of 13 csrs contained 
prostatitis; two, hyperplasia; and two, high-grade prostatic intraepithelial 
neoplasia.
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a b c
figure 3: Multi-parametric Mr imaging in axial plane performed in 59-year-old man with prostate-
specific antigen level of 10 ng/mL and history of three negative-result transrectal US–guided prostate 
biopsy procedures. (a) t2-weighted image, (b) diffusion-weighted imaging–derived\apparent diffusion 
coefficient map, and (c) dynamic contrast-enhanced volume transfer constant image. Outlined areas 
are suspected to be malignancy and were targeted by the robot for biopsy.
a b c
figure 4: Magnified views of (a) real-time axial Mr image on the ife and (b) robot controller. to align 
needle guide with suspicious region (depicted in figure 3), needle has to be adjusted to left. (b) software 
controller consists of multiple arrows corresponding to directions of potential needle guide movements. 
in this example, needle guide is moved to left by selecting arrow corresponding to this direction 
(highlighted in blue). (c) Confirmation axial MR image was obtained with biopsy needle in situ to verify 
position of needle (dashed red line) relative to desired csr (dashed yellow oval). histopathologic 
analysis revealed prostate cancer with gleason score of 3 + 4.
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discussion
in this study, we demonstrated the feasibility of adjusting the movement of the 
needle guide remotely throughout a transrectal prostate biopsy procedure. 
although the detection rate is not a crucial issue in feasibility studies, our cancer 
detection rate was 56% in patients with csrs, which is in concordance with the 
results reported in other lesion-directed Mr imaging–guided prostate biopsy studies 
(7–9). in our study, the median remote-controlled manipulation time for moving the 
needle guide from csr to csr was 2.5 minutes (range, 1–5 minutes). 
 other study investigators have reported on Mr imaging–guided robotic 
systems for prostate interventions in closed-bore systems (19–21). Muntener 
et al described a proof of principle for a fully automated robotic device for 
transperineal brachytherapy seed placement in dogs (19). van den Bosch et al 
recently conducted a proof of principle study, in which they used automated 
transperineal seed placement in one patient (21). in these studies, the perineum 
was used for seed placement during brachytherapy; this is a more desirable 
approach for increasing the therapeutic ratio in brachytherapy. for prostate 
biopsy, however, the transrectal approach is more favorable because it facilitates 
the possibility to perform biopsy without using anesthetics and increasing patient 
discomfort and complications (23,24). in addition, because using the transperineal 
approach requires a longer distance to the prostate than does the transrectal 
approach, errors due to needle deflection (28) and small deviations during the 
needle insertion may become more pronounced at farther distances from the 
insertion point, potentially decreasing biopsy accuracy. our robotic system was 
specifically designed for prostate biopsy and consists of an automated needle 
guide manipulation mechanism, whereas the transrectal biopsy itself had to be 
performed manually by the radiologist. 
 for practical reasons, because transverse us–guided prostate biopsy is far more 
accessible worldwide in terms of availability and skill in performing the procedure, 
the prostate cancer localization information attained with multi-parametric Mr 
imaging can be used to direct transverse us–guided biopsies. however, visually 
converting the localization information acquired with Mr imaging to gray-scale 
US data is associated with many difficulties—most likely at the expense of target 
accuracies. a solution could be automated transverse us–Mr imaging fusion. 
some preliminary published results with this technique have been promising 
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(29,30); however, more research with larger study populations is needed to 
demonstrate its clinical value. in terms of target accuracies, it is conceivable that 
Mr imaging–guided biopsy eventually will be the least adversely affected by 
spatial misregistration because the same two techniques are used for localization 
and biopsy. yet comparisons of target accuracy among the different biopsy 
techniques, such as transverse us–Mr imaging fusion– guided biopsy versus Mr 
imaging–guided biopsy, are lacking.
 our study had a number of limitations. the robotic device that we used in this 
preliminary study had restrictions related to the limited range and the size of the 
robot. Biopsies performed in patients positioned outside the pivoting point of the 
needle guide were not feasible with the robot. 
 also, owing to the size of the robot, some geometric limitations were 
encountered—specifically, some targets at the apex of the prostate were 
unreachable for biopsy. We also encountered some delays due to system 
integration issues. the image data were exported to the ife monitor in the procedure 
room. however, a number of required tasks—for example, measurement for biopsy 
depth planning and verification of the needle position after biopsy—were possible 
from behind the Mr console only. as a result, the operator had to repeatedly 
switch between the Mr console and the ife monitor during the procedure. We 
believe that these factors increased the procedure time by as much as 30–40 
minutes. in addition, target volumes were not calculated during the localization of 
the csrs on the diagnostic Mr images. as a result, we were unable to determine if 
the target volumes influenced the ability to successfully target these CSRs. 
 in future studies, after further optimizations of the robot (with a larger range of 
motion and a reduced robot size) and the system setup, investigation of biopsy 
accuracy and decreasing the biopsy procedure time seem to be the next logical 
steps. after a few adjustments, the robot may also be used in studies to investigate 
emerging treatments such as focal cryosurgery (31) and laser ablation (32) because 
it was designed to interact with a patient inside any standard closed-bore clinical 
MR system. These therapies might benefit considerably from the superior soft-
tissue contrast and temperature mapping ability (33) provided with Mr imaging 
for guiding intervention. in conclusion, it is feasible to perform transrectal prostate 
biopsy with real-time 3-t Mr imaging guidance by using a remote-controlled, 
pneumatically actuated Mr-compatible robotic device as an aid.
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abstract
purpose
the objective of this study was to assess the feasibility of magnetic resonance 
(Mr)-guided focal cryoablation at 1.5 tesla (t) in patients with locally recurrent 
prostate cancer (Pca) after initial radiotherapy. 
Materials and Methods
the need of informed consent was waived by the institutional review Board. 
ten consecutive patients with histopathologically proven locally recurrent Pca 
without evidence for distant metastases were treated with cryoablation under 
general anaesthesia in a 1.5t Mr scanner. a urethral-warmer was inserted and 
a transperineal template was placed against the perineum. cryoneedles were 
inserted under real-time Mr imaging. after correct placement of the needles, a 
rectal warmer was inserted. iceball growth was continuously monitored under Mr 
image guidance. two freeze-thaw cycles were performed. follow-up consisted 
of Psa-level measurement every three months and a multi-parametric Mri (MP-
Mri) after 3 and 6 months. Potential complications were recorded.
results
all patients were successfully treated with Mr-guided focal cryoablation. in 
one patient the urethral-warmer could not be inserted and the procedure was 
cancelled. two months later the patient was successfully treated. no other 
complications were recorded.
Follow-up is known for the first 6 patients. After three months, PSA levels of all 
patients had decreased and MP-Mri showed no signs of tumour recurrence. 
after six months, one patient had a local recurrence and was retreated with Mr-
guided cryoablation.
conclusion
transperineal Mr-guided focal cryoablation of recurrent Pca after radiotherapy 
is feasible and safe. initial results are promising, however longer follow-up is 
needed and more patients have to be included.
135
c
hapter 8
M
r guid
ed
 focal cryo-ablation
introduction
Prostate cancer (Pca) is the most common form of cancer in the western male 
population and has a significant socio-economic impact (1). Around 25–33% 
of newly diagnosed Pca patients undergo a form of radiotherapy. of these 
patients 26–52% develop biochemical signs of tumour recurrence within 5 years 
after treatment (2-4). after radiotherapy recurrence salvage prostatectomy is 
a frequently used therapy option. however, high rates of incontinence (0-67%) 
or rectal injury (0–8%) (5;6) have led to the search for other salvage treatment 
options. for this reason, ablative techniques such as cryoablation, high intensity 
focused ultrasound, and photodynamic therapy have been developed. 
 cryoablation, performed under transrectal ultrasound (trus)-guidance is 
an established treatment option for both men with newly diagnosed as well as 
recurrent Pca (7). a large study describing the results of salvage trus-guided 
cryoablation in 279 patients, reported an incontinence rate of 10.2%, and a recto-
urethral fistula rate of 1.1% (8). Other studies, concerning cryoablation under TRUS 
guidance, have described comparable results (9-11).
 furthermore, cryoablation has the ability to be used for focal therapy purposes. 
to our knowledge, only one study described trus-guided salvage hemi-ablation 
of the prostate (12).
 however, to be able to perform focal therapy, accurate and adequate image 
guidance is a prerequisite. trus is unable to provide accurate Pca localization 
and has major limitations in monitoring the iceball during cryoablation due to 
acoustic shadowing. Multi-parametric magnetic resonance imaging (MP-
Mri), comprising of t2-weighted, dynamic contrast enhanced, and diffusion 
weighted imaging is currently the best technique available for Pca localization. 
for detection and localization of Pca with MP-Mri, area’s under the curve of 
respectively 0.94–0.98 (13-15) and 0.71–0.95 (16-19) have been reported. During 
cryoablation, Mr image guidance enables accurate lesion targeting as well 
as three-dimensional monitoring of iceball growth, such that the Pca is treated 
completely and nearby critical structures are kept within a safe distance from the 
ice formation (20).
 nonetheless, Mr-guided prostate cryoablation is very uncommon. two studies 
described the first results of whole gland MR-guided cryoablation in patients with 
respectively newly diagnosed Pca or local recurrence after radiotherapy or 
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radical prostatectomy (21;22). 
 in contrast to the aforementioned studies which performed whole gland Mr-
guided cryoablation, this study describes initial results in focal Mr-guided salvage 
cryoablation. To our knowledge this is the first study to describe this. The purpose of 
this study was to assess the technical feasibility of Mr-guided focal cryoablation 
at 1.5t in patients with locally recurrent Pca after initial radiotherapy.
Materials and Methods
Preoperative Evaluation and Selection
from May 2011 to february 2012, 10 consecutive patients (median age, 67 
years; range, 52-76) with histopathologically proven PCa recurrence after initial 
radiotherapy and one patient with primary Pca were enrolled in this prospective 
study. all patients underwent a MP-Mri examination (3t MagnetoM skyra, 
siemens, erlangen, germany) with the use of a pelvic phased-array coil to 
localize recurrent cancer (figure 1) and to exclude bone- and node metastases. 
the need for informed consent was waived by the institutional review Board.
a b c
figure 1: Multi-parametric MRI Pre cryoablation. From left to right; Axial T2-weighted image of the 
prostate, axial aDc map, axial Dynamic contrast-enhanced Mr image. arrows pointing at the recurrent 
tumour.
MR-guided cryoablation
all patients were admitted in the hospital on the night before the cryoablation. 
Patients were prescribed antibiotics prophylaxis (ciProXin, Bayer, leverkusen, 
germany) for fourteen days, starting on the day before the cryoablation. Prior 
to the cryoablation they were instructed to give a self-administered cleansing 
enema to eliminate gas and remove faeces. 
 all patients were treated under general anaesthesia. after patients were 
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anaesthetized a catheter was inserted in the urethra, which was later during 
the procedure exchanged for a urethral warmer. Patients were positioned in 
a lithotomy position on the scanner table and cushions were used to maintain 
proper positioning and to make the patient as comfortable as possible. a pelvic 
phased array coil was placed over the patient’s pelvis. all procedures were 
performed by one interventional radiologist (JJF) using the MRI SeedNet System 
(galil Medical, yokneam, israel) in a closed bore 1.5t Mr system (MagnetoM 
avanto, siemens, erlangen, germany). all image parameters of the used 
sequences are described in table 1. 
 A transperineal template, attached to a flexible arm (Invivo, Schwerin, 
germany) was placed against the perineum of the patient. the template was 
moistened with sterile gel at forehand to improve its visibility on the Mr images. 
next, for cryoneedle placement, t2-weighted images in three directions 
were acquired to re-localize the recurrent tumour and the transperineal grid. 
cryoneedles (iceseed and/or icerod, galil Medical, yokneam, israel) were 
transperineally inserted in the tumour using real-time balanced steady-state free 
precession sequences which were projected onto a white screen in the Mr room. 
images were obtained in at least two directions to get an accurate impression 
of the needle position. after placement of all cryoneedles a rectal warmer was 
inserted in the rectum. Both warmers were continuously flushed with warm saline 
(43° Celsius) to protect the urethra and the rectal wall from freezing. The number 
and type of inserted cryoneedles was dependent on the size of the recurrent 
tumour, determined on the MP-Mri obtained during preoperative evaluation. 
Both needle types have distinct freezing characteristics. after ten minutes freezing 
the lethal zone of the iceseed and icerod are respectively 1x2 cm and 1.5x4 cm.
 iceball growth was continuously monitored using near real-time t1-weighted 
volumetric interpolated gradient echo Mr imaging (figure 2). the size and 
shape of the iceball were regulated by adjusting the gas flow to each individual 
cryoneedle. The iceball had to cover the total lesion with a definite safety margin. 
this safety margin was limited by avoiding contact of the iceball with the rectal 
wall. in total two freezing cycles were performed. each freezing period lasted 
10 minutes, or as long as the iceball remained within a safe distance from the 
critical structures. this safety distance was determined by carefully monitoring the 
position of the hyper intense iceball rim. active or passive thawing was continued 
until the cryoneedles were visible again on the Mr images.
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 after the second thawing period the cryoneedles were removed. the urethral 
warmer was flushed with warm saline for another 20-30 minutes to avoid strictures. 
Warming catheters were removed and another catheter was inserted in the 
urethra to avoid any temporary urinary incontinence or retention. this catheter 
could be removed after one or two days. Patients were asked to score potential 
pain according the numeric rating scale (nrs) when they were back on the 
nursing ward. When no complications occurred, patients were discharged the 
day after the procedure. Patients were prescribed movicolon (norgine, uxbridge, 
uk) for 3 weeks to ease defecation and were advised to drink a substantial 
amount of water in order to rinse the bladder. follow-up consisted of a MP-Mri of 
the prostate (figure 3) and a visit to the urologist after 3 and 6 months, to check 
for complications (i.e. urine retention, incontinence and rectal fistula), PSA level 
and local recurrence.
 in all procedures, total procedure- and treatment times were annotated. the 
total procedure time was defined as from the moment the patient entered the 
Mr suite and anaesthetization was started until anaesthetization was ended and 
the patient left the MR suite. Treatment time was defined as from the moment of 
the first MR image acquisition until the moment the last image acquisition was 
finished.
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table 1 imaging parameters Mr guided cryoablation protocol
protocol sequence tr (ms) te 
(ms)
flip angle 
(degrees)
voxel size 
(mm×mm×mm)
fov
(mmxmm)
acquisition 
time 
temporal 
resolution
 (s)
grid 
detection 
Balanced 
steady-state 
free Precession
607 0.99 70 2.5x2.5x8.0 480x480 8.2 s n.a.
t2wi axial, coronal 
and sagittal tse
5000 107 150 0.7x0.6x3.0 160x160 3:37 m n.a.
beat irt axial 
Balanced 
steady-state 
free Precession
465.92 1.82 70 2.7x2.7x10 350x350 n.a. 0.46
coronal/ sagittal 
Balanced 
steady-state 
free Precession
494.08 1.93 70 3.1x3.1x4.0 400x400 n.a. 0.49
t1 vibe axial volumetric 
interpolated 
gradient echo
4.81 1.96 6 1.3x1.3x2.5 250x250 0:50 m n.a.
t2wi = t2-weighted Mr imaging, vibe = volumetric interpolated breath hold examination, tse = turbo spin echo, ge = 
gradient echo, tr = repetition time, te = echo time, fov = field of view
a b c d
figure 2: a: axial t2-weighted image of the cryoneedles in situ. b-d: axial t1-weighted viBe with the 
growing ice ball (black signal void), eventually covering the entire tumour.
a b c
figure 3: Multi-parametric MRI 3 months post cryoablation. From left to right; Axial T2-weighted image of 
the prostate, axial aDc map, axial Dynamic contrast-enhanced Mr image. there is no sign of tumour rest.
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results
Feasibility
ten out twenty-three patients met the inclusion criteria and were successfully 
treated with Mr-guided focal cryoablation. one of these was a patient with 
newly-diagnosed Pca. he was previously treated with radiotherapy for testis 
carcinoma and for this reason, other therapies (surgery or salvage radiation 
therapy) were not possible. Patient characteristics are shown in table 2.1. 
table 2.1 patient characteristics
patient age (y) Months 
between rt 
and cryo
before rt before cryo-
ablation
gleason 
score
stage
(tnM)
psa
(ng/ml)
gleason 
score
stage psa
1† 65 80 7 n.a. 5.5 7 3b 2.7
2 66 52 6 3a 4 7 2 3.4
3* 67 n.a. n.a. n.a. n.a. 7 3 0.9
4 52 62 8 2-3 25 n.a. 2 8.7
5 68 76 6 1c 9 n.a. 2 8.4
6 71 55 8 3 19 9 2 7.2
7 60 119 8 2c 18 10 2 4
8 76 16 6 3a 14.6 7 2 7
9 67 30 7 1c 48 7 3b 3.1
10 68 24 7 2 12 n.a. 2 3.6
*Patient with newly diagnosed Pca and previous rt for testis carcinoma. 
n.a.= not available
†Patient had local recurrence and was treated again with Mr cryoablation.
Procedure and treatment time
the median procedure time was 210.5 minutes (range 179 – 375). the median 
treatment time was 133 minutes (range 91 – 242). Noteworthy, the first procedure 
had a procedure time and treatment time of respectively 375 and 242 minutes, 
the last procedure lasted only 184 and 91 minutes (figure 4). considering the total 
procedure time and the treatment time of all procedures, a substantial learning 
curve was noticed during the first 10 procedures (Table 2.2).
141
c
hapter 8
M
r guid
ed
 focal cryo-ablation
0
50
100
150
200
250
300
350
400
1 2 3 4 5 6 7 8 9 10
M
in
ut
es
patient
Procedure time
treatment time
Figure 4: Plot of the procedure time and the treatment time per patient, showing our learning curve.
table 2.2 procedure characteristics
patient procedure parameters follow up
number of 
cryoneedles
procedure 
time 
(minutes)
treatment 
time 
(minutes)
complications hospitalization 
days
3 months 6 months
psa Mp-Mri psa Mp-Mri
1† 4 375 242 Mild hema-
tospermia
3 2.2 no recur-
rence
2.9 recur-
rence†
2 3 300 138 none 2 0.5 no recur-
rence
0.5 no recur-
rence
3* 2 240 128 none 2 0.3 no recur-
rence
0.2 -
4 4 255 143 Mild urine 
retention, mild 
perineal pain
3 n.a. no recur-
rence
-
5 2 179 93 urine retention 2 1.3 no recur-
rence
- -
6 2 180 131 none 2 5.9 no recur-
rence
- -
7 4 217 135 none 2 - no recur-
rence
- -
8 2 186 94 none 2 - no recur-
rence
- -
9 3 204 140 none 2 - - - -
10 3 184 91 none 2 - - - -
*Patient with newly diagnosed Pca and previous rt for testis carcinoma. 
n.a. = not available, MP-Mri = multi-parametric Mri.
†Patient had local recurrence and was treated again with Mr cryoablation.
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Complications
All patients were satisfied about the treatment and hardly experienced any pain. 
in one patient the urethral-warmer could not be inserted due to perforation of 
the urethra and the procedure was cancelled. two months later the patient 
was successfully treated with focal MR-guided cryoablation. The first patient 
stayed a second night in the hospital at his own request. another patient had 
urine retention and was observed for a second night in the hospital. all other 
patients went home one day after the procedure. no other complications, like 
incontinence or fistula were recorded (Table 2.2).
Follow-up 
Follow-up is known for the first 6 patients. After three months, PSA levels decreased 
and MP-Mri showed no presence of recurrent tumour. two patients suffered 
from mild urine retention. after six months, one patient had a local recurrence 
just cranial to the previously treated area. This was the first patient treated with 
Mr-guided cryoablation at our institution, and when retrospectively examining 
the Mr images acquired during the procedure, it was found that treatment had 
been too conservative as the iceball did not cover the entire tumour. the patient 
was treated again with Mr-guided cryoablation and subsequent follow-up is not 
known yet.
discussion
in this study, the feasibility of Mr-guided focal cryoablation in patients with 
recurrent prostate cancer after radiation therapy was demonstrated. Most 
patients were discharged one day after the procedure and did not suffer from 
major complications. Patients who undergo salvage radical prostatectomy after 
radiotherapy are often hospitalized between 8 – 14 days (23).
 A true comparison between the results of our and other studies is difficult to 
make, because of the different patient characteristics groups (newly diagnosed 
vs. local recurrence) and treatment styles (whole gland vs. focal). in one study, 
whole gland Mr-guided prostate cryoablation was performed in 7 patients with 
newly diagnosed prostate cancer and 2 patients with local recurrence after 
radiotherapy in a wide-bore 1.5t Mr scanner (21). Per patient 4 – 7 cryoneedles 
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were used. One major complication was reported, a rectal fistula which 
spontaneously healed after 3 months. some minor complications as hematuria, 
dysuria and urine retention were reported as well. Mean hospitalization time was 
5.6 days (range 3 – 13). in another study 12 patients with local recurrence of 
Pca after radical prostatectomy were treated in a 1.5t wide-bore Mr scanner. 
Per patient 2 – 5 cryoneedles were used and 2 – 3 freeze-thaw cycles were 
performed. no instant complications were seen. however, within 3 months, one 
patient reported urine retention and in 2 patients local recurrence was found 
contiguous to the urethra (22).
 these above mentioned studies differed from our study in one important 
aspect. namely, whole gland treatment as opposed to study focal treatment 
in our study. only the lesion with a certain safety margin around it was ablated. 
By applying focal treatment, we aimed to keep a minimum of complications 
such as incontinence, impotence, and rectal fistula formation were tried to 
keep to a minimum. also, as a consequence of focal ablation, less needles (2–
4) were needed per patient. Probably for the same reason, the hospitalization 
time was shorter as well (2–3 days). When comparing our results with a study 
describing trus-guided salvage hemiablation of the prostate, they were more 
consistent. Per patient 2–4 cryoneedles were used and 2–4 freeze-thaw cycles 
were performed. Patients were discharged on the day of the procedure with 
a urine-catheter in situ for 2–5 days. furthermore, an incontinence rate of 6.7%, 
an erectile dysfunction rate of 60%, and no rectal fistulas were recorded. One 
patient harboured a residual carcinoma (12). 
 In our study longer term complications are only known for the first 6 patients. 
Psa levels decreased severely after three months. MP-Mri showed no presence 
of local recurrence. Mild urine retention was observed in two patients. after six 
months, the Psa level of one patient was increasing again and MP-Mri showed 
a recurrent tumour. therefore, Mr guided focal cryoablation was repeated. 
 one of main the reasons that Mr imaging guided cryoablation is suited 
for focal therapy is the potential for exact monitoring of the iceball formation. 
Previous studies described the presence of a hyper-intense border around the 
hypo-intense ice ball in fast t1-weighted imaging (24). this hyper-intense rim is 
caused by shortening of the T1 in cooled but not yet frozen tissue (25;26). By 
carefully monitoring this edge, exact ice ball can be monitored. in this way the 
tumour can be focally treated and nearby critical structures such as the urethra, 
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the rectal wall and the neurovascular bundle can be avoided. an alternative 
approach to obtain temperature information using Mri is to monitor the proton 
resonance frequency (Prf) shift. however, to enable Mr signal measurements 
from cooled tissue te has to be shortened, which in turn decreases temperature 
accuracy. additionally, the Prf-method is seriously affected by susceptibility 
artefacts at the ice-tissue transition (27). 
 this study encountered some limitations. foremost, a considerable learning 
curve was experienced. A lot of time was lost in finding the optimal workflow 
during the first procedures. Preparing the diagnostic MR-room for the procedure 
took a lot of time. furthermore, all Mr-guided cryoablation procedures were 
performed in a normal sized bore 1.5t Mr system (60 cm), which means limited 
amount of space for patient positioning as well as instrument handling for the 
physician. Proper patient positioning was therefore essential.
 for the purpose of creating more space for patient and instrument 
handling and improving image quality, the possibility of performing Mr-guided 
cryoablation in a wide-bore Mr scanner should be explored. other future steps 
will be to investigate the long term follow-up of the treated patients, to optimize 
the workflow, and to perform MR-guided cryoablation in combination with an 
MR-compatible robot (28). Workflow optimization and robotic needle placement, 
could further decrease the procedure and treatment time. 
 in conclusion, transperineal Mr-guided focal cryoablation of the prostate in 
patients with a local recurrence after radiotherapy was feasible and safe. initial 
results are promising, however longer follow-up is needed and more patients 
have to be included.
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chapter 2 discusses the potential role of MP-Mr imaging in focal therapy with 
respect to patient selection and directing (robot guided) biopsies and iMrt. an 
overview of the literature on Mri in the localization, staging, volume estimation, 
assessment of aggressiveness, and guidance of radiotherapy and biopsies in 
Pca has been provided. 
 for localization purposes areas under the curve (auc) of 0.90 have been 
reported when t2-w, Dce-Mri and Mrsi were combined. for local staging of 
PCa studies report maximum sensitivities and specificities of between 80%-88% 
and 96%-100%, respectively at a 3t Mr system (1, 2). not just in local staging, 
but also in staging of skeletal metastases Mr imaging is superior with a sensitivity 
and specificity of 100% and 88% compared to bone scintigraphy combined with 
targeted X-rays with a sensitivity and specificity of 63% and 64% (3). For lymph 
node metastases MR Lymphography (which uses a lymph node specific contrast 
agent, based on ultra-small superparamagnetic Particles of iron oxide) has a 
sensitivity of as high as 100% and a maximum specificity of as high as 97.8% 9 
(4, 5). DWI-MRI had a sensitivity of 86.0% and a specificity of 85.3% in one study 
(6). studies regarding volume measurement of Pca are few in number and 
not consistent, however some encouraging results with fair to good correlation 
have been presented (7-9). for determining Pca aggressiveness with DWi a 
significant negative correlation between Gleason grade and ADC values has 
been found for Pca located in the peripheral zone (10-12). in radiotherapy 
planning Mri does not yet have the ability to be used as treatment planning 
technique alone, ct is necessary for dose calculations. MrgB of the prostate 
has shown to improve cancer detection rate in subjects with an elevated Psa 
and repetitive negative trus-guided biopsies (13-17).
 in conclusion, MP-Mr imaging is a versatile, and promising technique. 
it appears to be the best available imaging technique at the moment in 
localizing, staging (primary as well as recurrent disease, and local as well as 
distant disease), determining aggressiveness, and volume of Pca. With this 
information guidance of focal therapy, iMrt and biopsy can be realized. it 
is recommended to perform MP-Mr imaging consisting of at least t2-w, Dce-
Mri, and DWi. however, larger study populations in multi-centre settings have 
to confirm these promising results. Yet before such studies can be performed, 
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more research is needed in order to achieve standardized imaging protocols. 
this is partly assessed in chapter 3. 
in chapter 3 the diagnostic performance of 3t, 3D Mrsi in the localization of Pca 
was compared with and without the use of an erc. this was a prospective study 
performed in 18 patients with histologically proven Pca on biopsy and scheduled 
for radical prostatectomy. all patients underwent 3D-Mrsi with and without an 
ERC. Readers independently rated their confidence that cancer was present in 
the prostate. These findings were correlated with whole-mount prostatectomy 
specimens. localization of Pca (in tumours of 0.5 cm3 or larger in volume) with 
MRSI with the use of an ERC had a significantly higher AUC (0.68) than MRSI 
without the use of an erc (0.63) (P = .015). Despite the fact that this difference 
was statistically significant, such a small increase in the AUC should make one 
think whether using the erc is worth the effort, cost and patient discomfort.
in chapter 4 the feasibility of 3t Dce-MrgB in localizing local recurrence of 
Pca after eBrt was evaluated in 24 consecutive men with biochemical failure 
suspected of local recurrence. In a first session patients are referred for a 
diagnostic Mri of the prostate, followed by, in a different session, MrgB. tissue 
sampling was successful in all patients and all tumour suspicious regions (tsrs). 
the positive predictive value on a per patient basis was 75% (15/20) and on a per 
tsr basis 68% (26/38). trus biopsy core schemes, which is the standard diagnostic 
work up in clinical practice in patients with a biochemical recurrence after eBrt, 
have a positive predictive value of 27% (18). these schemes use between 6-12 
cores per patient. in this study the median number of biopsies taken per patient 
was 3 and the duration of an MrgB session was 31 minutes. no intervention 
related complications occurred. in conclusion, the combination of diagnostic 
Mr imaging and MrgB of the prostate was a feasible technique to localize Pca 
recurrence after eBrt using a low number of cores in a clinically acceptable time.
in chapter 5 and 6 an overview of the literature, technical details, and future 
developments concerning MrgB of the prostate has been given. in men with 
an elevated Psa and/or abnormal Dre biopsy is the gold standard for Pca 
diagnosis. random systematic trusgB is the most widely applied and available 
Pca diagnosis method. Detection rates of Pca in random systematic trusgB 
153
c
hapter 9
sum
m
ary
do not exceed 44% and 22% for the first and second biopsy session, respectively 
(19, 20). consequently other biopsy methods have been explored. one of these 
methods is MrgB of the prostate that has detection rates after at least one 
previous negative trusgB session of between 38-59% (13-17). these rates are 
higher compared to repeat trusgB. for this reason MrgB will probably become 
more and more available in daily practice. however, the lack of standard 
protocols for Mr imaging of the prostate is an important issue. for the optimal 
biopsy technique there is still more research necessary. robotics may optimize 
MrgB regarding target accuracies and procedure time. this is partly assessed in 
chapter 7. 
in chapter 7 the feasibility of an Mr-compatible robot for MrgB was 
demonstrated. a total of 17 cancer suspicious regions (csrs) were detected in 10 
patients on the diagnostic multi-parametric Mr examinations. these csrs were 
targeted for Mr-guided robot assisted prostate biopsy. thirteen out of seventeen 
(76%) csrs were reachable for biopsy with the robot. the remaining 4 csrs were 
biopsied manually. in future studies, after further optimization of the robot (larger 
range of motion and size reduction) and the system set up, investigating biopsy 
accuracy and decreasing biopsy session time seem to be the next logical steps. 
in conclusion, it is feasible to perform transrectal prostate biopsy with real-time 3t 
Mr imaging guidance using a remote controlled, pneumatically actuated, Mr-
compatible, robotic device as an aid.
in chapter 8 the feasibility of Mr-guided focal cryo-ablation in recurrent Pca after 
radiotherapy was evaluated in 10 patients. all patients had histopathologically 
proven recurrent Pca, detected on MP-Mri, without evidence for distant 
metastases. they were treated with cryo-ablation under general anaesthesia in 
a 1.5T MR scanner. All patients were satisfied about the treatment and hardly 
experienced any pain. no major complications were recorded. follow-up is 
known for the first 6 patients. After three months, PSA levels of all patients had 
decreased and MP-Mri showed no signs of tumour recurrence. after six months, 
one patient had a local recurrence and was retreated with Mr-guided cryo-
ablation. transperineal Mr-guided focal cryo-ablation of recurrent Pca after 
radiotherapy is feasible and safe. initial results are promising, however longer 
follow-up is needed and more patients have to be included.
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conclusions
the following overall conclusions can be made:
1. Based on the literature, MP-Mr imaging appears to be the best 
available imaging technique currently in localizing, staging, determining 
aggressiveness, and volume of Pca (chapter 2).
2. Based on the literature, it is recommended to perform MP-Mri for the 
localization of Pca consisting of at least t2-w, Dce-Mri, and DWi for the 
highest diagnostic yield (chapter 2).
3. the use of an erc in 3D Mrsi in localizing Pca at 3t only slightly 
increases the localization performance compared to not using an 
erc (chapter 3).
4. Dynamic contrast-enhanced Mr targeted MrgB in patients with 
a biochemical recurrence after radiotherapy of Pca is a feasible 
technique (chapter 4). 
5. according to the literature, detection rates of MrgB of the prostate in 
patients with a history of previous negative trusgB sessions are higher 
compared to repeat trusgB (chapter 5 and 6).
6. it is feasible to perform transrectal prostate biopsy with real-time 3t Mr 
imaging guidance using a remote controlled, pneumatically actuated, 
Mr-compatible, robotic device as an aid (chapter 7).
7. transperineal Mr-guided focal cryo-ablation of recurrent Pca after 
radiotherapy is feasible and safe (chapter 8).
suggestions for future research
although Mr imaging in the management of Pca seems to be a promising 
technique most studies have been in single centres and concerned a low 
number of patients. these published initial results have to be validated in multi-
centre trials with larger number of patients. however before such trials can be 
performed uniform protocols have to be developed. Moreover a uniform scoring 
system concerning detecting/localizing Pca needs to be developed. recently 
the european society of urogenital radiology (21) has published guidelines with 
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an attempt to define standard imaging protocol requirements and a uniform 
scoring system. however, because of the lack of large multi-centre trials they 
have only been able to provide minimal requirements. also a uniform scoring 
system has been proposed by them. further clinical studies need to evaluate 
this proposed scoring system. One of the questions that need to be addressed is; 
should one of the MP-Mri techniques in a given clinical situation prevail above 
the other? in other words, should there be some kind of weighting factor for 
certain MP-Mri techniques in certain clinical situations?
 Basically this means; which combination of MP-MRI has the highest diagnostic 
performance in a certain clinical situation (e.g. primary Pca, recurrent Pca after 
radiotherapy (chapter 4) or after prostatectomy)?
 the necessity of the use of an erc for localizing primary Pca with Mrsi is one 
the research objectives of my thesis (chapter 3), the results of this study could 
serve in guidelines formation. this is an issue that also needs answering in the 
context of other MP-Mri techniques. not only the use of an erc but also for 
example issues concerning the use of a 1.5t versus a 3t Mr system need to be 
evaluated further.
 furthermore, in our work also some feasibility studies have been demonstrated. 
in optimizing the MrgB process the role of robotics has been partly investigated 
in chapter 7. the feasibility of MrgB with the aid of a Mr-compatible robot was 
demonstrated. the next step is to further optimize the biopsy setting and the 
robot itself. also future studies should focus on target accuracies and decreasing 
biopsy procedure time.
 We demonstrated the feasibility and safety of Mr guided focal cryo-ablation 
of the prostate (chapter 8). future studies should focus on a phase ii trial where 
a larger group of patients is treated. this should then be compared to the current 
standard of care which is whole gland cryo-ablation under trus guidance (e.g. 
in terms of complication rates, treatment success, hospitalization days, patient 
satisfaction, costs etc.).
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hoofdstuk 2 geeft een overzicht van de literatuur over de rol van Mri in de 
lokalisatie, het stadiëren, de volumeschatting, de bepaling van agressiviteit, en 
begeleiden van radiotherapie en biopten bij prostaatkanker.
 Psa, transrectaal onderzoek (Dre) en transrectale echo geleide biopsie 
(trusgB) hebben niet de mogelijkheid om prostaatkanker correct te lokaliseren, 
stadiëren, het volume en de agressiviteit te bepalen (1-6). in het nieuwe tijdperk 
van meer preciezere therapievormen, zoals minimaal focale behandelingen 
(bijv. cryochirurgie), is deze informatie van het grootste belang. De ideale 
diagnosetechniek bij prostaatkanker moet in staat zijn om deze informatie op 
een niet invasieve manier te verzamelen.
 voor lokalisatie is Mri een nauwkeurige techniek: de zogenaamde gebieden 
onder de receiver operating characteristic (roc)-curve hebben een waarde 
van 0,90 wanneer t2-gewogen (t2-w), dynamische contrast versterkende (Dce)-
Mri en Mr spectroscopie (Mrsi) werden gecombineerd. voor lokale stadiëring 
van prostaatkanker rapporteren studies een maximale sensitiviteit en specificiteit 
van 80% -88% en 96% -100%, respectievelijk op een 3 tesla (t) Mr-systeem (7, 8). 
niet alleen bij lokale stadiëring, maar ook bij het detecteren van skeletmetastasen 
is MRI superieur met een sensitiviteit en specificiteit van 100% en 88% ten opzichte 
van de botscan in combinatie met gerichte conventionele röntgen opnamen met 
een sensitiviteit en specificiteit van 63% en 64% (9). Voor lymfkliermetastasen heeft 
MR lymfografie (dat een lymfeklier specifieke contrastmiddel gebruikt, op basis 
van ultra-kleine superparamagnetische deeltjes van ijzeroxide) een gevoeligheid 
van maar liefst 100% en een maximum specificiteit van 97,8% (10, 11). Diffusie 
gewogen (DWI)-MRI had een sensitiviteit van 86,0% en een specificiteit van 85,3% 
in een studie (12). studies met betrekking tot volumemeting van prostaatkanker 
zijn weinig in aantal en niet consistent. er zijn echter een aantal bemoedigende 
resultaten gemeld (13-15). voor het bepalen van prostaatkanker agressiviteit 
met DWI is een significante negatieve correlatie tussen de Gleason score en 
de apparent diffusion coefficient ADC waarde gevonden met betrekking tot 
tumoren in de perifere zone van de prostaat (16-18).
 Multi-parametrische (MP) Mri is een veelzijdige en veelbelovende techniek. 
het lijkt de beste beschikbare beeldvormende techniek op dit moment in 
het lokaliseren, het stadiëren, het bepalen van agressiviteit, en het volume 
162
van prostaatkanker. het verdient aanbeveling om MP-Mri bestaande uit 
tenminste t2-w, Dce-Mri en DWi uit te voeren. echter, grotere studie populaties 
in meerdere instellingen moeten deze veelbelovende resultaten bevestigen. 
Maar voordat dergelijke studies kunnen worden uitgevoerd, is meer onderzoek 
nodig om gestandaardiseerde protocollen te kunnen formuleren. Dit wordt deels 
onderzocht in hoofdstuk 3.
in hoofdstuk 3 wordt de diagnostische waarde van 3t, 3-dimensionale (3D) 
Mrsi in de lokalisatie van prostaatkanker vergeleken met en zonder het gebruik 
van een endorectale spoel (erc). Dit was een prospectieve studie uitgevoerd 
bij 18 patiënten met een histologisch bewezen prostaatkanker middels biopsie 
en gepland voor radicale prostatectomie. alle patiënten ondergingen een 
3D-Mrsi met en zonder een erc. lezers beoordeelden waar in de prostaat 
de kanker aanwezig was onafhankelijk van elkaar. Deze bevindingen werden 
gecorreleerd met de radicale prostatectomie bevindingen. lokalisatie van 
prostaatkanker met MRSI met behulp van een ERC heeft een significant hogere 
roc-curve (0,68) dan Mrsi zonder het gebruik van een erc (0,63) (P = 0,015). 
Ondanks het feit dat dit verschil statistisch significant was, moet een dergelijke 
kleine stijging van de roc-curve afgewogen worden tegen de extra kosten die 
hiermee gemoeid zijn en het ongemak voor de patiënt tijdens het inbrengen 
van een erc.
in hoofdstuk 4 wordt de haalbaarheid van 3t Dce-Mr geleide biopsie (MrgB) 
geëvalueerd in het lokaliseren van een lokaal recidief van prostaatkanker na 
radiotherapie bij 24 mannen met biochemische verdenking op een lokaal 
recidief. MrgB was succesvol bij alle patiënten en alle tumor verdachte regio’s 
(tsr’s). De positief voorspellende waarde op een per patiënt basis was 75% 
(15/20) en op een per tsr basis van 68% (26/38). trusgB, dat de standaard 
diagnosetechniek in de klinische praktijk is, heeft bij patiënten met een 
biochemisch recidief na radiotherapie een positief voorspellende waarde 
van 27% (19) . Deze techniek maakt gebruik van tussen de 6-12 biopten per 
patiënt. in dit onderzoek bedroeg het gemiddelde aantal bioptien per patiënt 
3 en de duur van een MrgB sessie was 31 minuten. er waren geen interventie 
gerelateerde complicaties. Deze studie toonde aan dat de combinatie van 
MrgB en diagnostische Dce-Mri van de prostaat een haalbare techniek 
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was in het lokaliseren van prostaatkanker recidief na radiotherapie met 
een laag aantal biopten in een klinisch aanvaardbare tijd en een hoge 
detectiepercentage.
in hoofdstuk 5 en 6 wordt een overzicht van de literatuur, de technische details, 
en toekomstige ontwikkelingen met betrekking tot MrgB van de prostaat 
gegeven. Bij mannen met een verhoogd Psa en / of abnormale Dre is biopsie 
de gouden standaard voor prostaatkanker diagnose. Willekeurige systematische 
trusgB is de meest toegepaste en beschikbare diagnose methode. Detectie 
percentages bedragen 44% en 22% voor de eerste en tweede bioptie 
sessie, respectievelijk (20, 21). Dientengevolge zijn andere biopsie methoden 
onderzocht. een van deze methoden is MrgB, dat een detectie percentage 
heeft na ten minste één eerdere negatieve trusgB van tussen de 38-59% (22-
26). Deze percentages zijn hoger in vergelijking met herhaalde trusgB. om deze 
reden zal MrgB waarschijnlijk een belangrijke plaats in de dagelijkse praktijk gaan 
innemen. echter, het ontbreken van standaard biopsie protocollen voor Mri van 
de prostaat is een belangrijk punt. voor de optimale biopsie techniek is er nog 
meer onderzoek nodig. robotica kan mogelijk het MrgB proces optimaliseren 
met betrekking tot de nauwkeurigheid en de procedure tijd. Dit wordt deels 
onderzocht in hoofdstuk 7.
in hoofdstuk 7 wordt de haalbaarheid van een Mr-compatibele robot voor 
MrgB onderzocht. een totaal van 17 kanker verdachte regio’s (csr’s) werd 
aangetroffen in 10 patiënten met MP-Mri. Deze csr’s werden met behulp van 
de Mr-compatibele robot gebiopteerd. Dertien van de zeventien (76%) csr’s 
waren biopteerbaar met de robot. De resterende 4 csr’s werden handmatig 
gebiopteerd. in toekomstige studies, na verdere optimalisatie van de robot (groter 
bereik van de beweging en verkleining van het model) en de gehele opzet van 
het systeem, moet onderzoek gedaan worden naar de nauwkeurigheid en de 
snelheid van de robot.
in hoofdstuk 8 wordt de haalbaarheid van Mr-geleide focale cryo-ablatie bij 
recidief van prostaatkanker na radiotherapie geëvalueerd bij 10 patiënten. 
alle patiënten hadden histopathologisch bewezen recidief van prostaatkanker 
dat gedetecteerd was op de MP-Mri, zonder aanwijzingen voor metastasen 
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op afstand. zij werden behandeld met cryo-ablatie onder algehele anesthesie 
in een 1,5t Mr-scanner. alle patiënten waren tevreden over de behandeling 
en hadden nauwelijks pijn ervaren. er werden geen belangrijke complicaties 
geregistreerd. follow-up is bekend van de eerste 6 patiënten. na drie maanden 
was het Psa van alle patiënten gezakt en MP-Mri vertoonde geen tekenen van 
een recidief. na zes maanden, had een patiënt een lokaal recidief en werd 
wederom behandeld met Mr-geleide cryo-ablatie. transperineale Mr-geleide 
focale cryo-ablatie van recidief prostaatkanker na radiotherapie is haalbaar en 
veilig. De eerste resultaten zijn veelbelovend, maar langere follow-up is nodig en 
meer patiënten moeten worden geïncludeerd.
conclusies
1. op basis van de literatuur, MP-Mri lijkt de beste beschikbare beeldvormende 
techniek op dit moment in het lokaliseren, het stadiëren, het bepalen van 
agressiviteit, en het volume van prostaatkanker (hoofdstuk 2).
2. op basis van de literatuur, is het aanbevolen om voor de lokalisatie van 
prostaatkanker een MP-Mri te verrichten bestaande uit ten minste t2-w, 
Dce-Mri, en DWi (hoofdstuk 2).
3. het gebruik van een erc in 3D Mrsi in het lokaliseren van prostaatkanker 
op 3t geeft slechts in geringe mate een verbetering in vergelijking met het 
niet gebruiken van een erc (hoofdstuk 3).
4. Dce-Mri gerichte MrgB bij patiënten met een biochemisch recidief na 
radiotherapie van prostaatkanker is een haalbare techniek (hoofdstuk 4).
5. volgens de literatuur zijn detectiepercentages van MrgB van de prostaat 
bij patiënten met een voorgeschiedenis van eerdere negatieve trusgB 
sessies hoger dan herhaalde trusgB sessies (hoofdstuk 5 en 6).
6. het is mogelijk om transrectale prostaatbiopsie uit te voeren met 3t 
Mri begeleiding en met behulp van een op afstand bestuurbare Mr-
compatibele robot als hulpmiddel (hoofdstuk 7).
7. transperineale Mr-geleide focale cryo-ablatie van prostaatkankerrecidief 
na radiotherapie is uitvoerbaar en veilig (hoofdstuk 8).
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Prof. Dr. J. Barentsz, beste Jelle, bedankt voor het mogelijk maken van dit 
proefschrift. ik heb van jou de kans gekregen om me in de volste breedte te 
ontwikkelen en te ontplooien. ik besef me al te goed dat ik geboft heb met jou 
als promotor. 
Dr. J.J. Fütterer, beste Jurgen, ik wist dat ik altijd op jou kon rekenen. Altijd 
razendsnel met je commentaar op mijn stukken, iets wat ik altijd zeer heb 
gewaardeerd. van de coachende gesprekken die ik van tijd tot tijd van je heb 
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Derya yakar werd geboren op 25 april 1981 te nijmegen. in 1999 behaalde zij 
haar vWo diploma aan de nijmeegse scholengemeenschap groenewoud. na 
eerst 2 jaar filosofie te hebben gestudeerd in Nijmegen begon zij in 2002 met 
de geneeskunde opleiding aan de katholieke universiteit nijmegen. in 2008 
behaalde zij haar arts examen. een wetenschappelijke stage van 3 maanden bij 
de afdeling radiologie in het radboud over dynamische contrast versterkende 
Mri bij patiënten met een lokaal recidief van prostaatkanker na radiotherapie 
resulteerde in een publicatie. aansluitend werd in 2008 begonnen met het 
huidige project over Mri bij prostaatkanker onder leiding van prof. dr. Barentsz, 
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